National Guidelines for Clinical Management and Treatment of COVID-19

1st June, 2020

Version 4.0
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary of Updates</td>
<td>3</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
</tr>
<tr>
<td>Introduction to Coronaviruses (CoV)</td>
<td>4</td>
</tr>
<tr>
<td>Case Definition</td>
<td>4</td>
</tr>
<tr>
<td>Clinical Findings and Complications</td>
<td>5</td>
</tr>
<tr>
<td>Baseline Investigations</td>
<td>5</td>
</tr>
<tr>
<td>- Chemistry and Haematology</td>
<td></td>
</tr>
<tr>
<td>- Microbiology</td>
<td>6</td>
</tr>
<tr>
<td>- Radiology</td>
<td></td>
</tr>
<tr>
<td>Requesting COVID19 PCR test</td>
<td>7</td>
</tr>
<tr>
<td>Transport of Respiratory Secretions Samples</td>
<td>7</td>
</tr>
<tr>
<td>Medical Care for Patients with COVID19 infection</td>
<td>8</td>
</tr>
<tr>
<td>Dealing with Patients attending to Primary Health Care (PHC) or Accident and Emergency (AE)</td>
<td>8</td>
</tr>
<tr>
<td>Clinical Management and Treatment for confirmed COVID 19 cases</td>
<td>9</td>
</tr>
<tr>
<td>- Possible Therapeutics options</td>
<td></td>
</tr>
<tr>
<td>- Laboratory and Radiology Monitoring</td>
<td>10</td>
</tr>
<tr>
<td>- ECG Monitoring</td>
<td></td>
</tr>
<tr>
<td>Prognostic Factors &amp; Markers for Severe COVID-19 Disease</td>
<td>11</td>
</tr>
<tr>
<td>Treatment options</td>
<td>11</td>
</tr>
<tr>
<td>Table 1: Therapeutic Regimens for Adults</td>
<td>12</td>
</tr>
<tr>
<td>Camostat Mesylate</td>
<td>14</td>
</tr>
<tr>
<td>Favipiravir</td>
<td>15</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>15</td>
</tr>
<tr>
<td>Low dose corticosteroids</td>
<td>15</td>
</tr>
<tr>
<td>Addition of Multivitamins/supplements</td>
<td>15</td>
</tr>
<tr>
<td>Anakinra</td>
<td>16</td>
</tr>
<tr>
<td>VTE Thromboprophylaxis &amp; Anticoagulants use in COVID-19 patients</td>
<td>16</td>
</tr>
<tr>
<td>Non-Pharmacological Options</td>
<td>16</td>
</tr>
<tr>
<td>Tocilizumab “Protocol for severely ill ICU patients with COVID-19 Pneumonia”</td>
<td>17</td>
</tr>
<tr>
<td>Paediatric Patients COVID-19 treatment options</td>
<td>19</td>
</tr>
<tr>
<td>Paediatrics Tocilizumab Protocol for use in PICU patients</td>
<td>20</td>
</tr>
<tr>
<td>Pregnant patient</td>
<td>23</td>
</tr>
<tr>
<td>Medication Safety</td>
<td>23</td>
</tr>
<tr>
<td>Hydroxychloroquine &amp; G6PD Concerns</td>
<td>24</td>
</tr>
<tr>
<td>Discharge Criteria</td>
<td>25</td>
</tr>
<tr>
<td>Interim Guidance for De-isolation of COVID-19 Patients Version 1.0 (26 May 2020)</td>
<td>25</td>
</tr>
<tr>
<td>Infection Control Measures for Suspected Or Confirmed COVID19 Cases In Healthcare Facilities</td>
<td>26</td>
</tr>
<tr>
<td>Early Recognition</td>
<td></td>
</tr>
<tr>
<td>COVID 19 Visual Triage Form</td>
<td></td>
</tr>
<tr>
<td>Infection Control Practices In Healthcare Facilities</td>
<td>26</td>
</tr>
<tr>
<td>Training</td>
<td></td>
</tr>
<tr>
<td>General recommendations:</td>
<td></td>
</tr>
<tr>
<td>- Implement Standard Precautions for all patients at all times</td>
<td>27</td>
</tr>
<tr>
<td>Practice Airborne, droplet and contact Precaution when dealing with Suspected/Confirmed Cases</td>
<td></td>
</tr>
<tr>
<td>Personal Protective Equipment (PPE) for suspected or confirmed cases of COVID 19</td>
<td></td>
</tr>
<tr>
<td>Patient Care Equipment</td>
<td></td>
</tr>
</tbody>
</table>
Summary of Updates as of 1st June, 2020:

Positive case definition added Ag test.
Obesity is added as risk factor
Medication safety updated and Chloroquine dose adjusted
Medication table changes especially for critical cases.
Low dose steroids, anticoagulation, supplements added
Non-Pharmacological Options added
Occupational health for healthcare worker is published by public health
De- isolation changed as per national
Objectives

The objectives of this document are:

- To provide guidance on clinical management of the COVID-19 infection
- To provide a protocol on the practical steps to deal with COVID-19 cases
- To detail the measures necessary to protect hospital staff, patients and visitors
- Disclaimer added
- This guideline is not intended to override the clinical decisions that will be made by clinicians providing individualized patient care.
- This guideline will be updated as more information becomes available

Introduction to Coronaviruses (CoV)

- Corona virus is a large family of viruses that cause illness in humans and animals
- In people, Corona virus can cause illness ranging in severity from the common cold to Pneumonia and Severe Acute Respiratory Illness
- Corona virus is one of seven types of known human coronaviruses. SARS COV2 like the MERS and SARS coronaviruses, likely evolved from a virus previously found in animals
- The estimated incubation period is unknown and currently considered to be up to 14 days post exposure.

Case Definition:

Suspected COVID-19 case is defined as:
1. Please refer to the local health authority websites for updated information on local case definition.
   MOHAP, DoH, SEHA and DHA

Confirmed COVID-19 is defined as:
A person with confirmed positive COVID-19 test positive (SARS COV2 PCR), or positive Ag test by an approved laboratory.

Probable COVID19 is defined as:
A person with clinical and radiological picture compatible with CVOID19 infection awaiting PCR result or repeatedly Negative PCR tests collected from different sites with no microbiological evidence of another Infectious etiology.
Clinical Findings and Complications

Some patients with initially mild symptoms may progress over the course 5-7 days from symptom onset.

Clinical Symptoms: Signs and symptoms include:

- Fever
- Cough
- Myalgia or fatigue
- Shortness of breath
- Sore throat
- Runny nose
- Diarrhoea and nausea
- Muscle ache
- Headache
- Pneumonia and ARDS
- Loss of sense of smell
- Renal failure, pericarditis and Disseminated Intravascular Coagulation

Complications:

- Severe Pneumonia
- Acute Respiratory Failure and ARDS
- Acute Renal failure
- Disseminated intravascular coagulation
- Sepsis or septic shock

High-risk group

- Age above 60 years old
- Smoker
- Cardiovascular disease
- Diabetes
- Hypertension
- Obesity (BMI>30 or If Height not available, weight >100kg)
- Immune deficiency and or suppression (HIV/AIDS, long-term steroid therapy, post- transplant cases, chemotherapy, immune modulator therapy)
- Pre-existing pulmonary disease (uncontrolled Asthma, COPD, bronchiectasis)
- Other chronic disease such as chronic kidney disease, Chronic Respiratory disease, Sickle cell...etc.

Minimum baseline Investigations for a confirmed or probable COVID19

A set of minimum required baseline work up to be conducted for clinically stable patients when evaluating them in Isolation facilities, field hospitals, PHC Clinics or Emergency Departments to allow decision on required level of care and treatment Initiation:
1. Complete blood count
2. Renal function and Electrolytes
3. Random Glucose
4. Liver function test including ALT/AST
5. ECG if available
6. CRP if available
7. Chest X ray

**Investigations for confirmed or probable COVID19 patients admitted to hospitals**

**Chemistry and Haematology:**
1. Complete blood count and differential
2. Renal function and Electrolytes
3. Serum Glucose (HbA1C if diabetic)
4. Liver Function test including Liver enzymes
5. CRP
6. procalcitonin
7. G6PD (if treatment with chloroquine is being considered)
8. LDH
9. Coagulation profile
10. Ferritin
11. D-dimer
12. fibrinogen
13. Troponin & creatinine kinase (CK)
14. Pro BNP
15. HIV Ag/Ab
16. Pregnancy test in women of child-bearing age
17. Blood group

**Microbiology:**
SARS COV2 PCR on following samples
1. Deep respiratory samples (sputum or deep tracheal aspirate) if lower respiratory tract infection
2. Nasopharyngeal Aspirate/Swab and oropharyngeal swab (should use non-cotton flocked swab) if upper respiratory tract infection

**Staff should be trained on Sample collection.**

Health care workers collecting NP and OP swab specimens from suspected or confirmed COVID-19 patients should wear a clean, non-sterile, long-sleeve gown, a medical mask, eye protection (i.e., googles or face shield), and gloves. Procedure should be conducted in a separate/isolation room, and during NP specimen collection health care workers should request the patients to cover their mouth with a medical mask or tissue. 35

3. For intubated patients, obtain deep tracheal aspirate for:
   a) SARS-CoV2 PCR
b) Atypical PCR panel if available (Mycoplasma, chlamydia, legionella)
c) Respiratory viral panel
d) Other investigations to consider if the aetiology of the severe pneumonia is not identified:
   i. Legionella urinary antigen
   ii. Mycoplasma titres
   iii. AFB stain/culture Tuberculosis culture and PCR
   iv. Opportunistic pathogens in immunocompromised patients

All specimens should be regarded as potentially infectious, and HCWs who collect, or transport clinical specimens should adhere rigorously to standard precautions to minimize the possibility of exposure to pathogens.

Radiology

Ensure infection control measures are taken if patient is transferred to radiology or any other department outside the isolation room

1. CXR
2. Chest CT scan (HRCT or non-contrasted CT scan) is mandatory for all high-risk group patients admitted to hospitals and for patients with rapidly progressing illness. Consider CT scan chest while waiting COVID-19 PCR report as a diagnostic modality to guide early treatment and in patients with clinical features of pneumonia and normal chest X ray.
   (When mobilising patient ensure infection control measures are followed during and after transport)

Cardiac investigations:

3. ECG
4. Transthoracic Echocardiogram, pro-BNP, Troponin T and CK-MB if clinically indicated

Other tests If and when clinically indicated as per clinical condition and judgment of managing physician.

Requesting COVID19 PCR test:

<table>
<thead>
<tr>
<th>Governmental Facilities:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fill notification form and patient under investigation (PUI) form</td>
</tr>
<tr>
<td>Send the samples to their dedicated virology laboratory.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Private Facilities:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fill appropriate documents e.g. “Infectious Disease Reference Laboratory Request Form” or “Miscellaneous Request Form” accompanied by copy of Emirate ID or passport copy</td>
</tr>
<tr>
<td>Send samples after informing the laboratory in each district</td>
</tr>
</tbody>
</table>

| Abu Dhabi: Sheikh Khalifa Medical City |
| Dubai: Latifa Hospital |
| Northern Emirates: Al Qassimi Hospital, Sharjah |

Approved private laboratories

Transport of Respiratory Secretions Samples

Transport of the respiratory secretions sample to the reference laboratory of your district, using double packing system at 2-8°C temperature.
Trained personnel following safe handling practices should transport specimen

Medical Care for Patients with confirmed COVID-19 infection

- All suspected or confirmed cases should have the appropriate forms for public health filled and submitted to concerned Public Health Authority
- All confirmed cases should be screened for eligibility for treatment, as per UAE Health Authorities’ recommendation.
- All positive cases to be assessed, if fitting criteria for institutional isolation, can be isolated at designated isolation building, with full instructions and to inform PH/PHC/OPD for follow up
- If patient’s condition deteriorates, they will be transferred to the nearest healthcare facility for further assessment and management.
- Admit patients with stable moderate illness and patients with mild illness and risk factors to hospitals/ field hospital /isolation facilities and follow active treatment pathway according to the clinical data.
- If patient’s condition deteriorates, upgrade level of care, with immediate arrangement for transfer to hospital if elsewhere with proper communication with receiving facility
- Admit all severe and critically ill patients to hospitals and once their condition stabilizes, they can be transferred to lower levels of care areas.
- Admit all patients with COVID19 infection to single rooms with good ventilation and separate toilet, unless aerosol generating procedures is anticipated then in a room with Negative Pressure Ventilation.
- If hospital capacity is full, positive COVID 19 cases can be cohorted in the same room, provided there is 6 feet distance between the patients.
- Implement standard, contact and droplet precautions whenever coming in contact with positive cases. (Appendix I). Unless aerosol generating procedure then, airborne precaution.
- Follow recommended active management plan for patients with moderate to severe illness.

Dealing with Patients attending Primary Health Care (PHC) or Accident and Emergency (AE)

*Suspected cases if admitted need to be in a single room with droplet precaution unless aerosol generating procedure then, airborne precaution.

<table>
<thead>
<tr>
<th>Clinical Scenario</th>
<th>Decision</th>
</tr>
</thead>
<tbody>
<tr>
<td>No symptoms</td>
<td>• COVID19 testing is not indicated</td>
</tr>
<tr>
<td>Not meeting case definition</td>
<td>• Reassure and discharge</td>
</tr>
<tr>
<td>Meeting case definition</td>
<td>• Collect sample for lab-based SARS CoV2 PCR on Respiratory samples</td>
</tr>
<tr>
<td></td>
<td>• Fill required notification forms</td>
</tr>
<tr>
<td></td>
<td>• Respiratory Panel test if available</td>
</tr>
<tr>
<td></td>
<td>• Baseline work up and chest X ray are indicated</td>
</tr>
<tr>
<td></td>
<td>• If there is evidence of an alternate diagnosis and the patient is stable; less likely to be COVID19, and manage accordingly, however, it does not rule out coinfection with COVID-19</td>
</tr>
</tbody>
</table>
• Admission, discharge or transfer decision should be based on clinical stability and baseline work up results.
• If discharged, quarantine at home/institution pending PCR results
• If first COVID19 test is Positive, follow Positive cases management pathway
• If first COVID19 test is Negative, and clinical presentation and investigation is suggestive of COVID-19, repeat SARS CoV2 PCR

Clinical Management and Treatment for confirmed COVID 19 cases

Disclaimer:
1. This document is a guideline and NOT a substitute for good clinical practice and judgment of clinician for individual cases
2. Literature is rapidly evolving & this document may not necessarily reflect all the updated day to day information.
3. Guidelines will be reviewed by National Committee can be modified/updated if National committee deems it necessary in case of significant, high quality substantial evidence emerge against or in favor of any of the pharmacological options.

• Treat all positive cases of COVID-19 when indicated as early as possible.
• Apply Standard Precautions, Contact Precautions, and Droplet Precautions with eye protection should always be used when caring for the patient
• If asymptomatic or mild symptoms can be cared for in single room with good ventilation and droplet precaution. Negative pressure rooms are not required unless aerosol generating procedures or anticipating these procedures.
• Clinical management includes prompt implementation of recommended infection prevention and control measures and supportive management of complications, including advanced organ support if indicated.
• There is no specific approved treatment for COVID19 infection to date. However, FDA has issued emergency use authorization for Chloroquine and Hydroxychloroquine. FDA has also published recommendations for investigational COVID19 Convalescent Plasma. See table below
  o Give low flow oxygen therapy to mild pneumonia cases regardless of their saturations. For moderate and severe cases, oxygen to be given as per their clinical requirements.
  o Consider awake proning for eligible patient regardless of level of care. (see appendix II)
  o Use conservative fluid management, whenever possible.
  o Only use empiric antimicrobials if evidence of super added bacterial infection, and preferably narrow spectrum, if clinically indicated.
  o Closely monitor patients for signs of clinical deterioration.
  o Use prophylaxis low molecular weight heparin if no contraindications.
  o Address co-morbid condition(s).
**Pharmacological options:** (Based on limited available information’s, expert’s opinion & in view of regional and/or international dynamics of practice)

1. National committee strongly encourage clinicians to maximize the efforts to start, participate in clinical trials to bring maximum patients in context of clinical trials.
2. Strict monitoring patient for drug induced potential harms and timely intervention in case of any early signals of possible treatment related potential harm

- If the patient is admitted to a private hospital and Active treatment is indicated, but not available, Public Health and Health Regulations in concerned Emirate/Health Authority to be contacted.

**Laboratory and Radiological Monitoring**

- Baseline tests should be done prior to treatment initiation for all patients.
- Repeat PCR test after 5 days of positive swab collection date.
- Thereafter, repeat blood tests every 72 hours and imaging every week, unless clinically indicated earlier, while on treatment.
- Repeat more frequently in critically ill patients if indicated

**Recommended monitoring parameters for Drug Therapy management**

- CBC, Renal Profile and extended electrolytes (Na+, K+, Mg++, Ca++, Phosphate), Uric Acid, Hepatic Profile, Serum Amylase, Serum Lipase, Coagulation profile,
- G6PD test baseline
- Blood glucose in patients with Chloroquine or hydroxychloroquine, frequent blood glucose monitoring is required in diabetic patients as risk of hypoglycaemia is high ((may require adjusting Insulin or other diabetic medications dosing)

**ECG Monitoring:**

Perform Baseline ECG on every patient and may repeat every 24 to 48 hours for patients suspected to have QT prolongation, or high risk for QT prolongation i.e.

- Elderly, female gender, patients with electrolytes imbalance (Hypokalaemia, Hypomagnesemia, Hypophosphatemia, Hypocalcaemia etc.) if low level of any these electrolytes, immediately replace it, keep serum K+ > 4mmol/L
- History of cardiac arrhythmia, Bradycardia, Heart disease (Myocarditis, pericarditis, and cardiomyopathy may increase risk for arrhythmia)
- On concurrent QTc prolonging drugs or in the recent past patient has taken QT prolonging drugs with long half-life e.g Amiodarone, Azithromycin, Fluoxetine etc for other QT prolonging drugs check Pharmacokinetic i.e. half-life for the specific drug
- Following are just few examples of QT prolonging drug classes (Fluoroquinolones, Macrolides, Azoles antifungals, Ibradidine, Anti-emetics, Anti-depressants, Antipsychotics, Antiarrhythmic etc (Avoid these and any other QT prolonging drugs in patient on COVID-19 treatment) for more details check on following link
  - www.qtdrugs.org
If a COVID-19 patient needs antibiotic to cover for atypical micro-organism in case of concurrent community acquired bacterial pneumonia, then **Doxycycline** should be choice in view relative safety of Doxycycline on QT prolongation, can be used with Chloroquine/Hydroxychloroquine

*Doxycycline can be as an alternative to Macrolides & Fluroquinolones if indicated in patients with QT issues*

### Prognostic Factors & Markers for Severe COVID-19 Disease

<table>
<thead>
<tr>
<th>Epidemiological- Category 1</th>
<th>Vital signs- Category 2</th>
<th>Labs-Category 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt; 55</td>
<td>Respiratory rate&gt;24 breaths/min</td>
<td>D-dimer&gt;1000 ng/mL</td>
</tr>
<tr>
<td>Pre-existing pulmonary disease</td>
<td>Heart rate &gt; 125 beats/min</td>
<td>CPK&gt;twice upper limit of normal</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>SpO2 &lt;90% on ambient air</td>
<td>CRP&gt;100</td>
</tr>
<tr>
<td>Diabetes with A1c&gt;7.6%</td>
<td></td>
<td>LDH&gt;245 U/L</td>
</tr>
<tr>
<td>History of hypertension</td>
<td></td>
<td>Elevated troponin</td>
</tr>
<tr>
<td>History of Cardiovascular disease</td>
<td></td>
<td>Admission absolute lymphocyte count&lt;0.8</td>
</tr>
<tr>
<td>Use of biologics</td>
<td></td>
<td>Ferritin&gt;300 ug/L</td>
</tr>
<tr>
<td>Obesity (BMI&gt;30 or If Height not available, weight &gt;100kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>History of transplant or other immunosuppression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients with HIV (regardless of CD4 count)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Treatment Options:
- The various treatment options including regimens are provided in table 1
- Any drug-induced side effect to be managed accordingly
- **Rule out pregnancy before starting Favipiravir, Ribavirin etc**
- **Favipiravir, Ribavirin** are absolutely contraindicated in pregnancy
- **Check details in Medication safety information** section regarding Favipiravir, Ribavirin before prescribing any of these drug for women with child bearing age & and male patients who female partner is already pregnant or can be pregnant during & 7 days after end of treatment with Favipiravir, and during or up to 6 months after end of treatment with Ribavirin
- Get Informed consent from patient for treatment of COVID19, if patient can’t provide consent then his family member /guardian
Table 1: Therapeutic Regimens for Adults

- There is no approved therapy for COVID19 to date. Medications used are off label or experimental, based on best available data.
- Chloroquine dose is according to Chloroquine Phosphate salt NOT on Chloroquine Base
- For patients having renal or hepatic impairment, consult individual drug monograph for additional monitoring or dose adjustment.
- Baseline Monitoring parameters and early initiation of treatment is highly advisable

Chloroquine Serious Warnings: Potential serious risk of QT prolongation & fatal arrhythmia Torsades de pointes, ventricular fibrillation, cardiac arrest.

1. Careful use & strict screening, monitoring of patient risk factors for QT prolongation (for details see ECG monitoring section)
2. Avoid QT prolonging drug during & even after 3 to 5 days of stopping Chloroquine [26] and 6-8 weeks after stopping Hydroxychloroquine (Half life 40 days) in patients with high risk for QT prolongation (If use of significantly QT prolonging drugs after stopping of Chloroquine & Hydroxychloroquine during this wash out period then, strict monitoring of ECG and correction of electrolytes and close monitoring of patient condition by clinicians)
3. Do Not use Chloroquine, Hydroxychloroquine before at least 3-5 days period after stopping Azithromycin, if not possible, strictly monitor ECG and patient condition
4. Should avoid use of Hydroxychloroquine, chloroquine concurrently or within 8-10 weeks of stopping Amiodarone as half life of Amiodarone is very long (average 58 days) ,do not start Amiodarone with in 6-8 weeks of stopping Hydroxychloroquine if possible (If use of significantly QT prolonging drugs after stopping of Chloroquine & Hydroxychloroquine during this wash out period is unavoidable, then strict monitoring of ECG and correction of electrolytes and close monitoring of patient condition by clinicians)
5. For other QT prolonging drugs avoid overlap period depending upon medication pharmacokinetic parameters.

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Suggested Medications</th>
</tr>
</thead>
</table>
| Clinical presentation | Dosing & frequency mentioned is for normal Renal & Hepatic Functions
For Moderate to severe Hepatic Impairment & or severe Renal impairment, Drug interaction etc.
(Consult individual drug monograph for additional monitoring or dose adjustment) |
| Contact               | No Post exposure Prophylaxis is indicated for the time being |
| Probable case of COVID-19 URTI without pneumonia | Please follow the confirmed case management |
| Probable case of COVID-19 Pneumonia (see Probable case definition above) | Please follow the confirmed case management |
| Confirmed COVID19 | No treatment,  
| Asymptomatic | **High risk:** Age above 60 years old, Cardiovascular disease, hypertension, Diabetics, Pre-existing lung disease, or Immunocompromised / cancer patients, (Obesity (BMI>30 or If Height not available, weight >100kg)  
| | **If high risk:**  
| | **Chloroquine Phosphate** 500 mg PO BID X 2 doses then 250 mg PO BID (total 5 days)  
| | OR  
| | **Hydroxychloroquine** 400mg PO BID X 2 doses then 200mg PO BID (total 5 days)  
| | If radiological evidence of pneumonia, follow pneumonia recommendation  
|  
| Confirmed COVID19 | **Hydroxychloroquine** 400mg PO BID then 200 mg PO BID (total 5 days)  
| URTI without Pneumonia For 5 Days | OR  
| | **Chloroquine Phosphate** 500 mg PO BID X 2 doses then 250 mg PO BID (total 5 days)  
| | OR  
| | **Favipiravir** 1600 mg PO BID X 2 doses then 600 mg PO BID (total 5 days)  
| | OR  
| | **Lopinavir-Ritonavir** (200/50 mg) 2 tablets PO BID [7] (Total 5 days)  
| | • Addition of Camostat 200 mg PO TID X 5 days optional on case by case basis as per treating physician choice (if available)  
|  
| Confirmed COVID19 | **Favipiravir** 1600 mg PO BID X 2 doses then 600 mg PO BID (total 7 days) [8,13]  
| Pneumonia For 7 days | +**Hydroxychloroquine** 400mg PO BID X 2 doses then 200mg PO BID (total 5 to 7 days) ± Camostat 200 mg PO TID for 5 to 7 days (if available and optional)  
| | OR  
| | **Favipiravir** 1600 mg PO BID X 2 doses then 600 mg PO BID from day2 (total 7 days) +Chloroquine Phosphate 500 mg PO BID X 2 doses then 250 mg PO BID (total 5 to 7 days) ± Camostat 200 mg PO TID for 5 to 7 days (if available and optional)  
| | OR  
| | **Lopinavir-Ritonavir** (200/50 mg) 2 tablets PO BID (total 7 days) [7] + **Hydroxychloroquine** 400 mg PO BID X 2 doses, then 200 mg PO BID (total 5 to 7 days) (alternatively Chloroquine 500 mg PO BID X 2 doses, then 250 mg PO BID) (5 to 7 days) ± Camostat 200 mg PO TID (5 to 7 days) (if available and optional)  
| | OR  
| | **Remdesivir** 200 mg IV on day 1, followed by 100 mg IV daily [8,15,40]  
|  
| Confirmed COVID19 | **Favipiravir** 1600 mg PO BID X 2 doses then 600 mg PO BID +Camostat 200 mg PO TID ± nebulized Interferon Alpha or Interferon Beta (for 5 days) through Nebulizer creating fine mist (ultrasonic nebuliser) e.g. Aerogen Nebulizer (Do NOT use Pegasys or any other pegylated interferon for Nebulization)  
| Severe Pneumonia /Critically Ill patients For 10 days | OR  
| | **Lopinavir-Ritonavir** (200/50 mg) 2 tablets PO BID +Ribavirin* 400 m PO BID for 7 days PLUS Interferon [40]. through Nebulizer creating fine mist e.g. Aerogen Nebulizer (Do NOT use Pegasys or any other pegylated interferon for nebulization)  
| | **Interferon Formulations & dosing for nebulization:** No specific dosing established for COVID-19 through nebulization for both formulations, dosing frequency, duration mentioned below are based on suggestion of National committee Physician members from MOH, DHA in view of their limited experience Depending upon Availability:  
| | **Interferon Alpha 2b 5 million units** /ampule (Bioferon) dilute 2 ampules with 4 ml of normal saline, use BID X 5 days via ultrasonic nebulization
Interferon beta 1b (Betaferon) Interferon beta 1b 8 million units (250 microgram) Subcutaneous on alternative days for 3 doses or use through Nebulization 8 million units (250 microgram)/vial, mix reconstituted solution of 1 vial of Betaferon with 2 ml of normal saline BID X 5 days

* = Contra-Indications for Ribavirin \(^{[41]}\) Hypersensitivity, Pregnancy, males whose wives are pregnant, concomitant use with didanosine, autoimmune hepatitis, fatal hepatic failure, pancreatitis, hemoglobinopathy (thalassemia major, sickle cell anaemia), CrCl <50 ml/minute (for pregnancy & teratogenic risk check medication safety information section)

OR

Remdesivir 200 mg IV on day 1, followed by 100 mg IV daily [8,15,\(^{[41]}\)]

For ICU patients consider empirical antibiotics if bacterial co-infection is suspected according to individual hospital protocol/guideline

Anticoagulation (see details below)
Steroids (see details below)
Tocilizumab to be considered in case of cytokine storm (see details below)
Convalescent plasma to be considered as experimental therapy (see details below)

Camostat Mesylate

Camostat Mesylate\(^{[14]}\) is approved drug for medical use in Japan for more than 10 years in other indications like: Chronic Pancreatitis, Post surgery reflux esophagitis (Specific dosing regimen information for COVID-19 Not yet available the doses suggested in the guidelines are based on extrapolation from approved dosing regimens for above mentioned other indications.)

• According to research in Germany on SARS-2 Virus of COVID-19 attack on Lung cells in laboratory setting showed that Camostat Mesylate inhibited TMPRSS 2 partially & resulted in ~ 50 % blockage of attack through ACE2 receptors pathway. “Hoffmann et al., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”, Cell (2020), https://doi.org/10.1016/j.cell.2020.02.052.\(^{[14]}\)

• As per their recommendation the drug should be tried in clinical studies

Clinical Studies/Trials:\(^{[36]}\)

To date 5 clinical trials registered with clinicaltrials.gov (2 in USA,1 in Denmark,1 in Germany,1 in Israel) to evaluate the efficacy of Camostat in RCT, so far no published information’s /findings, however expectations from the drug to show efficacy in early course of disease to prevent or minimize progression of disease into severe form.

Safety profile: Overall safe drug, rarely Hyperkalaemia, Eosinophilia with pneumonitis, urticaria etc.
Favipiravir:

Dose may need adjustment based on clinical scenario, **Patient is elderly or any patient with other risk factors for CKD and develops** AKI i.e 50% rise in serum creatinine from baseline during course of Favipiravir and the rise is persistent

**Persistent rise in serum creatinine without any other possible obvious medical reason i.e**

- No other nephrotoxic drugs,
- No hypotension or hypertensive emergency
- No sepsis,
- No dehydration
- No other medical cause of rise in serum creatinine (i.e no recent exposure to contrast).

In these patients strict intake/output monitoring with daily serum urea & creatinine and correct any other reason i.e. dehydration, hypotension..etc. If rise is persistent despite all corrective actions then can modify dose and/or minimize duration or stop/hold to avoid permanent renal injury in high risk patients for renal toxicity i.e. elderly, diabetic, HTN, Heart diseases, other nephrotoxic medications.

For individual case it is advised to consult Nephrologist & clinical pharmacist for their input to advise based on risks vs benefits

**Remdesivir: [7,13,40]**

Remdesivir has Emergency use authorization from FDA. Explain risks vs benefits to patient’s, strict monitoring of patient clinical condition, documentation & reporting of significant or serious adverse drug reactions is required.

**Low dose corticosteroids**

Low dose corticosteroids in early Course of disease may have possible benefit in some patients (In patients with moderate to severe pneumonia on case by case basis as per decision of primary team based on risks vs benefits)

**Addition of Low Dose Early corticosteroids in moderate to severe COVID-19 Pneumonia [38]:** As per the pre-print of Quasi Experimental pre-test (81 pts), post-test (132 pts) study at Henry ford hospital USA. In post test Early use of short course of IV Methylprednisolone 0.5-1 mg/kg in 2 divided dose X3 days in Non ICU & 5-7 days in ICU patients reduced composite end points (hospital length of stay, reduced progression of disease, all-cause mortality) in post-test group [Raef Fadel, Austin Morrison, Amit Vahia, Zachary R Smith, Zohra Chaudhry etal, https://www.medrxiv.org/content/10.1101/2020.05.04.20074609v1

**Addition of Multivitamins/supplements [45,46]**

Vitamin C 1000 mg PO BID, Vitamin-D 50000 units weekly for 2 weeks (currently being investigated in clinical trials) may have possible add on benefit

**Addition of Elemental Zinc [39,42,43,44]:** Addition of Elemental Zinc 50 mg PO daily for 5 to 7 days in patients with Hydroxychloroquine therapy may be beneficial according to one retrospective study Philip Carlucci, Tania Ahuja et al, doi: https://doi.org/10.1101/2020.05.02.2008003 (also currently
being investigated in clinical trials), the similar benefits is expected from chloroquine as well because it acts as Zinc Ionophore\[42,43\] (increase zinc transport into cells hence zinc in high concentration can possibly inhibit virus replication)

**Anakinra:**

Anakinra can be a possible alternative to Tocilizumab in case of shortage of Tocilizumab or contra-indications, the decision to use Tocilizumab or Anakinra should be in consultation with hospital rheumatologist (if available) and MRP as an multidisciplinary team decision

**VTE Thromboprophylaxis & Anticoagulants use in COVID-19 patients:**

Use according to institutional protocol/policy, use prophylactic anticoagulant in all admitted COVID 19 patients irrespective of VTE risk if no contra-indications to use of anticoagulant

Intermittent pneumatic compression devices should be considered if there is a contra-indication to the use of prophylactic anticoagulation.

**Interferons**

Use being investigated in different clinical studies, Interferon beta 1 b used as 8 million units Sub-Q on alternative days for 3 doses in triple therapy in phase 2 trial in Hongkong by Prof Ivan Fan Ngai Hung et al DOI :https://doi.org/10.1016/S0140-6736(20)31042-4

Interferon Alpha 2B and other interferon of Alpha group also being evaluated for COVID-19

**Non-Pharmacological Options**

**Convalescent plasma** (In context of clinical trial):

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has several therapies which are undergoing investigation, but the efficacy of these drugs is yet to be established, furthermore, the use of convalescent plasma was recommended as treatment during former viral infections, therefore, there is a hypothesis that convalescent plasma might be efficacious in the treatment of patients infected with COVID-19. However, there is limited evidence from a few, very small studies that its use is beneficial in these patients, and more recent studies demonstrated its potential benefit when administered to non-intubated patients.

**Therefore, COVID-19 convalescent plasma is recommended as follow:**

Cases in the serious category with COVID pneumonia and oxygen requirements are the preferred candidates and we recommend to introduce COVID-19 convalescent plasma (CCP) treatment early in the admission process, patients should have their cardiac enzyme, ECG, renal function and Pro-BNP performed and patient should not demonstrate any cardiac or renal compromise prior to administration of CCP.

CCP is not recommended for the life-threatening intubated patients’ category unless it’s for compassionate use and in a case by case basis.

Two doses that are 48 hours apart is recommended, exception to the second dose are patients who either demonstrates a dramatic improvement or deterioration in their cardiac and/or renal status.
Extra Corporeal Blood purification therapies in Cytokine Release syndrome in critically ill COVID-19 patients (In context of clinical trial):

COVID-19 patients can present with a cytokine release syndrome (CRS) and severe acute respiratory failure induced by high level of circulating cytokines levels. Currently there are limited options for patients who deteriorate requiring Intensive care. In view of the complexity of the immune response in response to COVID-19, and the resulting CRS, it is likely that a specific therapy directed against a single cytokine, may not be completely effective in modulating a very dysregulated inflammatory response.

Current therapeutic options in context of COVID-19 related CRS have been limited to experimental antibody-based therapies (e.g. tocilizumab, intravenous immunoglobulins (IVIgG) and convalescent plasma administration.

Extra Corporeal Blood purification (ECBP) has been proposed to remove cytokines in patients with sepsis and systemic inflammatory (1, 2, 3, 4). The rationale for use of these ECBP is that these extracorporeal adsorption membranes are used in cytokine removal, and potentially could improve immune homeostasis and perhaps might help prevent CRS-induced organ damage (2, 6). In addition neither haemodialysis nor hemadsorption appear to remove molecules such as IgG and Tocilizumab as their size (e.g., 150 kDa for IgG, Tocilizumab 148 kDa) exceeds the upper size of molecules mainly being removed these therapies (around 60 kDa)(7). Hence these ECBP therapies will not preclude the use of the other experimental therapies on a compassionate use.

The U.S. Food and Drug Administration have recently provided an emergency use authorization of 4 Extra Corporeal Blood purification devices to treat acute respiratory failure in COVID-19 in context of clinical trials.

1. Oxiris Set device  https://www.fda.gov/media/137267/download
2. SeraPh 100 Microbind Affinity Blood Filter https://www.fda.gov/media/137101/download
4. CytoSorb device https://www.fda.gov/media/136867/download

There are multiple clinical trials underway in assess effectiveness of this approach.

ClinicalTrials.gov Identifier: NCT04358003, NCT04344080, NCT04385771, NCT04324528

These devices such as Cytosorb, HA330, Depuro D200 have theoretical value in the management of COVID-19 disease and some anecdotal evidence; however, actual clinical trial data that establish true efficacy are lacking even as the body of anecdotal evidence of benefits expands rapidly. For these reasons, among patients who have been admitted to Intensive Care Unit with COVID-19 related acute respiratory failure, the U.A.E COVID guideline writing panel recommends that “Extra Corporeal Blood purification therapies may be offered to patients with acute respiratory failure in the context of a clinical trial to improve patient access to these devices and to increase clinical knowledge”

Adults Tocilizumab Protocol for critically ill patients with COVID-19 Pneumonia[7,13,24,37]

(Do Not Use Sub-Q formulation pre-filled syringes, autoinjectors to prepare IV Solutions) Use only Commercial product specific for IV use

The decision to use Tocilizumab or Anakinra should be in consultation with ID or Rheumatologist and MRP as a multidisciplinary team decision

Tocilizumab for Cytokine Release syndrome (CRS):
It is FDA approved drug for treatment of CRS due to (Chimeric antigenic T-Cell therapy): Chimeric antigenic T-Cell therapy that works as an IL-6 receptor inhibitor; It is FDA approved drug for
treatment of cytokine storm syndrome following Chimeric Antigen Receptor T cell (CAR-T) therapy for B cell malignancies and in Macrophage Activation Syndrome, conditions that share several immune features with COVID-19.

- **Tocilizumab** For severely ill ICU patients with COVID-19 Pneumonia remains investigational and off-label. Therefore, caution in prescribing it is warranted.

  **Severe Form of Disease:** Adults who meet any one of the following:

  1. Shortness of breath, RR > 30 breaths/minute;
  2. Oxygen saturation < 93% at rest
  3. Arterial oxygen partial pressure (PaO2)/ fraction of inspired oxygen (FiO2) < 300mmHg (1mmHg = 0.133 kPa)

**Determine severity and intervention of Cytokine release syndrome**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Mild reaction</td>
<td>No treatment with tocilizumab</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Moderate reaction, fever, need for IV fluid (not hypotension), mild oxygen requirement</td>
<td>Send for serum IL-6</td>
</tr>
</tbody>
</table>
| Grade 3 | Severe, liver test dysfunction, kidney injury, IVF for resuscitation, low dose vasopressor, supplemental oxygen (high flow, BiPAP, CPAP) | 1. Send for serum IL-6, and screening tests (hepatitis B surface Antigen and antibody, hepatitis B core antibody, hepatitis C, quantiferon)  
  2. Consider tocilizumab after sending screening tests. If no response, consider low dose corticosteroids |
| Grade 4 | Life-threatening, mechanical ventilation, high dose vasopressors | 1. Send for serum IL-6  
  2. Consider tocilizumab as Grade 3; consider corticosteroids |

**Indication criteria for Use of Tocilizumab**[^7,15]

- Extensive and bilateral lung disease and severely ill patients with elevated IL-6 level alternatively High levels of d-dimer and/or CRP/ or ferritin and/or fibrinogen progressively increasing.
- Worsening of respiratory exchanges such as to require non-invasive or invasive support from ventilation

**Laboratory Parameters also supportive of cytokine storm**[^26]

- Serum IL-6 ≥ 10x upper normal limit
- Ferritin >300 ug/L (or surrogate) with doubling within 24 hours
- Ferritin >600 ug/L at presentation
- and LDH >250 U/L
- Elevated D-dimer (>1 mg/L)
- High CRP

**Tocilizumab Exclusion Criteria of Patients:**[^7,15,24]

- Active TB
- AST /ALT values higher than 5 times the normal levels.
- Neutrophil value lower than 500 cells/mm³
- Platelets value lower than 50,000 cells/mm³
- Complicated diverticulitis or intestinal perforation
Confirmed systemic bacterial & or fungal infection (i.e. Bacteraemia with pathogenic bacteria, fungemia)

- Pregnant women (there are insufficient data about its safety in pregnancy)
  - Skin infection in progress (e.g. dermohypodermatitis not controlled by antibiotic therapy)
  - Immunosuppressive anti-rejection therapy

**Adult Tocilizumab Dosing Regimen [24,41]**

*(Need to Send IL-6 level prior to giving first dose of Tocilizumab)*

- The suggested dose is 4-8 mg/kg body weight (maximum dose 800 mg) X Once only

**Administration:** Dilute in 100 ml of 0.9 % saline, allow diluted solution to reach room temperature, infuse over more > 60 minutes using dedicated line (Do Not infuse if opaque particles or discoloration visible same)

If partial or incomplete clinical response POSSIBLE second infusion maybe given 8-12 hrs after the first dose (Maximum 2 doses)

**Pediatric Patients COVID-19 treatment options**

Due to the limited data at this point in time, the current approach is on different protocols from some countries, ongoing investigations for some of the drugs in adults & extrapolated from available evidence from adult based studies

- Treatment in Paediatric patients on case by case basis after consultation with ID Physician and concerned speciality
- Get Informed consent from patient for treatment of COVID19, If patient can’t provide consent then his family member /guardian
- * Chloroquine dose is according to Chloroquine Phosphate salt NOT on Chloroquine Base
  - Consideration of antiviral therapy in combination with Hydroxychloroquine or Chloroquine should be based on patient condition, safety profile and preference of the patient and primary team in consultation with Paediatric infectious diseases physician
  - Total duration of treatment with Chloroquine /Hydroxychloroquine should not be more than 5-7 days
  - Nebulized interferon alpha 2b, Interferon Beta 1b may be a possible option in addition to Kaletra (Lopinavir-Ritonavir), chloroquine, Hydroxychloroquine in critically ill paediatric patients
  - Interferon should not be routine option for all PICU patients, in very rare cases based on thorough evaluation of serious risks vs benefits by MRP with ID, may be used. (For Interferon dosing check Lexicomp & or product leaflet/prescribing informations for general dosing according to individual patient need, if need any adjustment or not).

- If patient is already on Interferon discontinue it (If considering use of Tocilizumab)
- At least 24-48 hrs gap after last dose of regular interferon, and
- At least 3-5 days gap after ‘Pegylated Interferon (taking into consideration average half-life)’ before starting Tocilizumab.
- Do Not use or restart systemic Interferon therapy in patient who received Tocilizumab

<table>
<thead>
<tr>
<th>Clinical Presentation</th>
<th>Suggested Medications (for paediatrics)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Confirmed COVID 19</td>
<td>Follow the below recommendations</td>
</tr>
</tbody>
</table>
### Asymptomatic

<table>
<thead>
<tr>
<th>Drug</th>
<th>No treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>General dosing</td>
<td>Avoid Hydroxychloroquine/Chloroquine in critically ill/PICU patients</td>
</tr>
</tbody>
</table>

#### Hydroxychloroquine Sulfate

<table>
<thead>
<tr>
<th>Loading Dose</th>
<th>Maintenance</th>
<th>Dose (Per Oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.5 mg/kg PO (Maximum 400 mg per dose) BID X 2 doses</td>
<td>3.25 mg/kg PO (maximum 200 mg per dose) BID X 4 days (total duration 5 days)</td>
<td>[10,20,21]</td>
</tr>
</tbody>
</table>

#### Chloroquine Phosphate

<table>
<thead>
<tr>
<th>Chloroquine Loading dose Day One</th>
<th>Maintenance dose from day two</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.3 mg/kg Once (Maximum 500 mg per dose)</td>
<td>5 mg/kg once daily (250 mg per day) X 4 Days (total duration 5 days)</td>
</tr>
</tbody>
</table>

#### Lopinavir/Ritonavir

<table>
<thead>
<tr>
<th>Weight-directed dosing (Children and Adolescents) (Per oral)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15 kg: Lopinavir 12 mg/3 mg /kg/dose PO  twice daily</td>
</tr>
<tr>
<td>15 to 40 kg: Lopinavir 10 mg/2.5 mg/kg/dose PO twice daily</td>
</tr>
<tr>
<td>&gt;40 kg: Lopinavir 400 mg/100 mg PO twice daily</td>
</tr>
</tbody>
</table>

Favipiravir dosing is in patients ≥ 12 months of Age & body weight ≥10kg
(There is no data regarding use & dosing in COVID-19, doses in below table derived & modified from Ebola study in 12 children)

<table>
<thead>
<tr>
<th>Body weight</th>
<th>Favipiravir 200 mg Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-15 kg</td>
<td>Loading Dose: One tablet PO BID for One day (maximum 400 mg/day) Maintenance from Day2: Half tablet (100 mg) PO BID (maximum 200 mg/day)</td>
</tr>
<tr>
<td>16-21 kg</td>
<td>Loading Dose: Two tablets PO BID One day (maximum 800 mg/day) Maintenance from Day2: One Tablet PO BID (maximum 400 mg/day)</td>
</tr>
<tr>
<td>22-35 kg</td>
<td>Loading Dose: Three tablets PO BID for One day (maximum 1200 mg/day) Maintenance from Day2: One tablet PO TID (maximum 600 mg/day)</td>
</tr>
<tr>
<td>36-45 kg</td>
<td>Loading Dose: Four tablets PO BID for One day (maximum 1600mg/day) Maintenance from Day2: Two tablets PO BID (maximum 800 mg/day)</td>
</tr>
<tr>
<td>46-55 kg</td>
<td>Loading Dose: Five tablets PO BID for One day (maximum 2000 mg/day) Maintenance from Day2: Two tablets qAM, thee Tablets qPM (maximum 1000 mg/day)</td>
</tr>
<tr>
<td>For &gt;55 kg</td>
<td>Can use adult dosing if age ≥16 years, if age &lt;16years use dosing of 46-55 kg range</td>
</tr>
</tbody>
</table>

---

**Pediatrics Tocilizumab Protocol for use in PICU patients**[26] ≥ 2 years

Currently under investigation for use in the treatment of COVID-19 associated pulmonary complications with elevated IL-6 levels (see ClinicalTrials.gov). **Safety & efficacy is not yet established for COVID-19 at this time point in time. (use only IV commercial formulation, Do Not use Sub-Q prefilled syringes/pens)**

Use restricted to Intensivist & ID only AND COVID-19 positive patients with severe ARDS after failing or not qualifying for first line treatments

◊ **Risks of serious toxicity including serious hepatotoxicity leading to fulminant liver failure & cases of liver transplant in past, life threatening secondary infection & or other side effects vs benefits need to be assessed and discussed with patient guardian/family & clearly explained & informed consent to be signed by father/ guardian**

**Need to send for IL-6 Level before starting therapy with Tocilizumab ideally**
### Severe Form of Disease in Children [7]:

- Children who meet any one of the following:
  - Show shortness of breath (<2 months old, RR > 60 times/min;)
  - 2~12 months old, RR > 50 times/min;
  - 1~5 years old, RR > 40 times/min; except the effects of fever and crying;
  - Oxygen saturation <92% at rest.

Laboured breathing (wheezing, flaring of nostrils, three concave sign), cyanosis, intermittent apnoea.

- Lethargy, convulsions.
- Refusal to eat or difficulty feeding; signs of dehydration.

### Critical form of Disease:

- Meeting any of the following criteria:
  - Respiratory failure occurs and mechanical ventilation is required, Shock,
  - Combined failure of other organs that requires ICU monitoring

**In Paediatric ICU** if patient is in *early ARDS and Possible Cytokine Storm* as per criteria set in Tocilizumab protocol and may be a candidate for Tocilizumab, **THEN Do-Not Start Interferon** as high risk of potential serious side effects concurrently with two Immune modulating drugs (i.e. Tocilizumab, Interferon).

### Indication criteria for Use of Tocilizumab [7,15,23,25]

- Extensive and bilateral lung disease and severely ill patients with elevated IL-6 level

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
<th>Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>mild reaction</td>
<td>No treatment with tocilizumab</td>
</tr>
<tr>
<td>Grade 2</td>
<td>moderate reaction, fever, need for IV fluid (not hypotension), mild oxygen requirement</td>
<td>Send for serum IL-6</td>
</tr>
<tr>
<td>Grade 3</td>
<td>severe, liver test dysfunction, kidney injury, IVF for resuscitation, low dose vasopressor, supplemental oxygen (high flow, BiPAP, CPAP)</td>
<td>Send for serum IL-6, and screening tests (hepatitis B surface Antigen and antibody, hepatitis B core antibody, hepatitis C, QuantiFERON) Consider tocilizumab after sending screening tests. If no response, consider low dose corticosteroids</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Life-threatening, mechanical ventilation, high dose vasopressors</td>
<td>Send for serum IL-6, Consider tocilizumab as Grade 3; consider corticosteroids</td>
</tr>
</tbody>
</table>
Alternatively, High levels of d-dimer and / or CRP/ or ferritin and / or fibrinogen progressively increasing.

Worsening of respiratory exchanges such as to require non-invasive or invasive support from ventilation

**Laboratory Parameters also supportive of cytokine storm** \(^{[25]}\)

The inflammatory markers criteria should be in context of IL-6 along with other markers mentioned below

- Serum IL-6 > 10 x upper normal limit
- Ferritin >300 mg/L (or surrogate) with doubling within 24 hours
- Ferritin >600 mg/L at presentation
- and LDH >250 U/L
- Elevated D-dimer (>1 mg/L)
- High CRP

**Tocilizumab Exclusion Criteria of Patient:** \(^{[7,15,24]}\)

- Active TB
- AST / ALT values higher than 5 times the normal levels.
- Neutrophil value lower than 500 cells / mm\(^3\)
- Platelets value lower than 50,000 cells /mm\(^3\)
- Complicated diverticulitis or intestinal perforation
- Skin infection in progress (e.g. dermohypodermatitis not controlled by antibiotic therapy)
- Immunosuppressive anti-rejection therapy
- Confirmed systemic bacterial & or fungal infection (i.e. Bacteraemia with pathogenic bacteria, fungemia)

**Tocilizumab dosing in Pediatrics ≥ 2 years** \(^{[24]}\):

- IV: 8 mg/kg/dose (maximum 400 mg per dose) X Once
  - **Administration:** Dilute in 100 ml of 0.9 % saline, allow diluted solution to reach room temperature, infuse over 60 minutes using dedicated line (Do Not infuse if opaque particles or discoloration visible same)
  - **Administration:** Dilute in 100 ml of 0.9 % saline, allow diluted solution to reach room temperature, infuse over 60 minutes using dedicated line (Do Not infuse if opaque particles or discoloration visible same)

**Explanation for Calculation of “Favipiravir dosing” for COVID-19 in paediatrics**

**Use of Favipiravir** \(^{[19,20]}\) (Avigan) In Paediatrics’ ≥ 12 months of Age & body weight ≥10kg. As such no dosing information data available from any ongoing or proposed trial or study in Paediatrics’ in COVID-19.

Dosing regimens were derived dosing from the doses used in Ebola Trial \(^{[19]}\)in 12 children ≥ 12 months of Age & body weight ≥10kg \(^{[19]}\) (dosing regimen derived on almost similar scale used in adults from Ebola to COVID-19 regimen)

For Adult patients Favipiravir (Avigan) COVID-19 Dosing is less than Ebola dosing i.e. (COVID-19 Loading dose is 50% less ,maintenance dose 25%-50% less compared to Ebola dosing ) based on almost similar scale it is plausible to adopt the same strategy in children for dose reduction as well for the safety reasons and hence COVID-19 dosing were adopted for “Paediatrics”

In children of lower body weight range i.e. 10-15 & 16-21 kg range more conservative dosing approach adopted due to safety concerns.
Pregnant patients:

- In Pregnant Patients management of COVID-19 Case by case basis with ID Consultation and obstetrician.
- Nebulized interferon alpha 2b, Interferon Beta 1b can be a possible option in addition to Kaletra (Lopinavir-Ritonavir), chloroquine, Hydroxychloroquine in pregnant women for details of specific formulations dosing, method, duration, check treatment section for severe pneumonia/ critically ill adult patients (page 11-12)

**Medications Safety Information**
For more details about the suggested medications, refer to Appendix VII-COVID -19 Treatment Options Index

**Drug Use Management of COVID-19 Patients**

*Follow the basic principle of Medicine” First Do No Harm”*

COVID -19 patients are often with underlying diseases receiving multiple types of drugs, at risk for adverse effects.

The following is expected from every healthcare giver to ensure safety of treatment options

- **Strict compliance** to Labs, ECG monitoring Parameters (mentioned in this guideline)
- **Side Effects Monitoring**, prompt action accordingly
- **Check for Drug interaction & if dose adjustment required when patient is on COVID-19 drugs**

**Nursing monitoring Parameters:**

- For any potential side effects and inform MD on Duty “
- Strict Monitoring of Glucose, Hypoglycaemia especially in diabetic or NPO, Insulin & Diabetic medications dose adjustment may be required case on cases basis
- Monitor sign of arrhythmia, immediately inform MD

**Pregnancy Warning with “Avigan” (Favipiravir)**

**Avigan is contra-indicated in pregnancy**
When administering AVIGAN® (Favipiravir) to women of child-bearing potential, rule out pregnancy before starting the treatment. Explain fully the risks and instruct thoroughly to use most effective contraceptive methods with her partner during and for 7 days after the end of the treatment. If pregnancy is suspected during the treatment, instruct to discontinue the treatment immediately and to consult a doctor.

**Advice for Male patient**

AVIGAN (Favipiravir) is distributed in sperm. When administering the drug to male patients, explain fully the risks and instruct thoroughly to use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of the treatment (men must wear a condom). In addition, instruct not to have sexual intercourse with pregnant women during & for 7 days after the end of the treatment.
Favipiravir in Breastfeeding /Lactation: When administering Favipiravir to lactating women, instruct to stop lactating (The major metabolite of Favipiravir, a hydroxylated form, was found to be distributed in breast milk.)

Pregnancy Warning with Ribavirin: Teratogenic, serious foetal abnormalities absolutely Contra-indicated

Significant teratogenic and/or embryonical effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple dose half-life of 12 days, and it may persist in non-plasma compartments for as long as 6 months.

Therefore, ribavirin, is contraindicated in women who are pregnant and in the male partners of women who are pregnant.

Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of therapy in both female patients and in female partners of male patients who are taking ribavirin therapy. At least two reliable forms of effective contraception must be utilized during treatment and during the 6-month post treatment follow-up period.

Rule out pregnancy before starting treatment whenever applicable

• Check for any potential drug interaction if patient is on any other medication or being started while on COVID-19 treatment
• Avoid concurrent use of Macrolides, and other QT prolonging drugs in patient with chloroquine, Hydroxychloroquine therapy
• Keep monitoring patient clinically for any early sign of potential drug adverse effect and take prompt action to assess the patient regimen and manage accordingly

Hydroxychloroquine & G6PD Concerns:

• " In Lexicomp Drug information source: It mentions as precaution not Contra-indication for G6PD deficiency: Although the manufacturer’s labelling recommends hydroxychloroquine be used with caution in patients with G6PD deficiency due to a potential for haemolytic anaemia, there is limited data to support this risk. Many experts consider hydroxychloroquine, when given in usual therapeutic doses to WHO Class II and III G6PD deficient patients, to probably be safe (Cappellini 2008; Glader 2017; Luzzatto 2016; Youngster 2010). Safety in Class I G6PD deficiency (ie, severe form of the deficiency associated with chronic hemolytic anemia) is generally unknown (Glader 2017). In a retrospective chart review, no incidence of hemolytic anemia was found among the 11 patients identified with G6PD deficiency receiving hydroxychloroquine therapy, despite >700 months of exposure (all patients were African American and located in the US) (Mohammad
In addition, the ACR Rheumatology guidelines do not mention the need to evaluate G6PD levels prior to initiation of therapy (Singh 2016).

- So, if used, exercise cautions and monitor closely for any early sign of Hemolytic anemia & manage accordingly

**Discharge Criteria for COVID19 confirmed cases**

- if COVID19 PCR test from nasopharyngeal sample or lower respiratory sample is positive, repeat samples after 5 days from the positive swab and every 72 hours thereafter.
- Once a sample becomes negative, collect after 24 hours
- for De-isolation of COVID-19 Patients, please refer to:

**Interim Guidance for De-isolation of COVID-19 Patients Version 1.0 (26 May 2020)**

**C. Moderate, severe, and critical symptomatic hospitalized COVID-19 positive patients:**

- **Test-based strategy:**

  Patient can be discharged once they have:
  - Two consecutive respiratory specimens negative tests for COVID 19 that are ≥ 24 hours apart and
  - Patient is afebrile for more than 3 days without the use of fever-reducing medications and
  - Patient has improved/minimal respiratory symptoms and
  - Pulmonary imaging (CXR/ HRCT) shows significant improvement

- All patients after discharge should be self-isolated at home for 7 days from discharge date and to have a sick leave documented in medical record

- Discharged patients to be followed in the clinic in the hospital after 2 weeks, unless patient develops respiratory symptoms to attend earlier.

- If asymptomatic at 2 weeks, no more follow up

- Notify Public health/Preventive medicine at discharge.

**Note:** Healthcare worker who test positive for COVID 19 should return to work as soon as possible once they are symptom free and have 2 consecutive negative PCR that are ≥ 24 hours apart.
Infection Control Measures for Suspected or Confirmed COVID19 Cases in Healthcare Facilities

Early Recognition

Enhance early recognition of suspected cases by:

- Visual triage at the entry point of the healthcare facility, for early identification of all patients with acute respiratory illness (ARI).
- Visual triage station should be placed at the entry point of the AE and any entry point attended by a trained nurse or nurse assistant. Staff should be trained on appropriate questions to ask as well as actions based on findings and updated case definition.
- Post visual alert signage to enhance self-reporting by symptomatic patients.
- Provide enough supply of surgical masks & hand hygiene sanitizers in the AE room.
- All identified acute respiratory infection (ARI) patients should be offered to wear a surgical mask, if they can tolerate it, and should be asked to perform hand hygiene.
- All contacts of suspected patients should also be offered to wear a surgical mask and should be asked to perform hand hygiene.
- Do not allow suspected COVID19 into common areas with other patients.
- Place suspected COVID19 in a dedicated waiting area with at least 3 feet and preferably 6 feet distance between them.
- Screen all patients walking into the ED for symptoms of acute respiratory illness (ARI) using the COVID-19 visual triage form below.
- Perform Infection Control Risk Assessment in triage.

Infection Control Practices in Healthcare Facilities:

Training

- All healthcare workers entering these rooms should be trained on proper use of PPE and fit tested in order to use N95. (Appendix I)
- Ensure that patients and visitors receive education about the precautions being used; the duration of precautions; the prevention of transmission of infection to others; and use of appropriate PPE.
- Ensure that front line staff as well as other staff at risks i.e. radiology, respiratory therapist; cleaning staff receive training on COVID19 preventative strategies.

*The mode of transmission of COVID 19 remains unknown.*

General recommendations:

Implement Standard Precautions for all patients at all times focusing on

- Hand hygiene: adherence to WHO steps and moments
- Ensure availability and Proper use of PPE.
• Follow Respiratory Hygiene Practices:
  o Offer a medical mask for suspected cases of COVID 19 for those who can tolerate it.
  o Educate patient and relatives about cough and sneeze etiquette ie. Cover nose and mouth during coughing or sneezing with tissue or flexed elbow for others.
  o Avoid touching your eyes, mouth or nose.
  o Post visual aid for cough etiquette, hand hygiene and symptoms to report early.
• Risk assessment is critical for all activities, i.e. assess each health care activity and determine the personal protective equipment (PPE) that is needed for adequate protection.

Practice droplet and contact Precaution when dealing with Suspected Cases (Appendix I)

For suspected cases:
Patients to be placed in a single room with its own toilet.

Practise droplet and contact precautions for suspected cases:

• Wear a surgical mask, eye protection i.e. goggles or a face shield, gloves and impermeable gown.
• Practice airborne precautions for aerosol-generating procedures (wear fit tested N95 mask) as (bronchoscopy, open suction, nebulization, sputum induction, ambu-bagging intubation and extubation, BiPAP, CPR, and autopsy

Practice droplet and contact Precaution when dealing with Confirmed Cases

For confirmed cases:
• Place patient in a single room with good ventilation and with its own toilet, with the door closed.
  Airborne infection isolation room is only required if aerosol generating procedure is anticipated.
• If a negative pressure, room is needed for aerosol generation procedures but not available, put the patient in a single room, well ventilated, and place air disinfectant (Plasma air filter or Portable HEPA filter) in the room, next to patient’s head.
• Practise droplet and contact precautions for confirmed cases unless aerosol generating procedure.
• HCP should wear respiratory protection equivalent to a fitted N95 filtering facepiece respirator or equivalent N95 respirator during aerosol-generating procedures.
• Unprotected HCP should not be allowed in a room where an aerosol-generating procedure has been conducted until sufficient time has elapsed to remove potentially infectious particles as per room air exchange per hour
• Conduct environmental surface cleaning following procedures (see section on environmental infection control).
• Avoid the presence of unnecessary individuals in the room.
• Practice airborne precautions for aerosol-generating procedures
• Note that high risk patients may present with mild symptoms but are at high risk of deterioration.

Personal Protective Equipment (PPE) for confirmed cases of COVID 19

PPE should be available where and when it is indicated in the correct size and sufficient quantity

• Ensure all staff wear surgical mask, eye protection i.e. goggles or a face shield, gloves, head cover and impermeable gown in the usual setting, however, if aerosol generating procedure or prolonged stay in patient’s room then use a fit-tested N95 or equivalent.

• Designate staff who will be responsible for caring for suspected or known COVID-19 patients. Ensure they are trained on the infection prevention and control recommendations for COVID-19 and proper use of personal protective equipment.

• All health care provider should wear and remove the PPE safely.

• If there is concern and/or breach of PPE during patient care, leave the patient care area when safe to do so and properly remove and change the PPE and report it to your direct line manager and infection control Practitioner/unit

• Minimize the time spent and entry to the patient room by cohorting the task together

• All PPE should be used for certain task with certain patient and should be removed and discarded before leaving the patient room except N95 will be removed immediately outside patient room

• In case of shortage of PPE, refer to WHO and CDC guidelines for extended use/reuse of PPE

Patient Care Equipment

• When possible use disposable devices or equipment.

• If disposables devices and equipment not an option, dedicate devices or equipment to a single patient

• If dedicated devices or equipment is not available, clean and disinfect the shared equipment before using it for other patients with approved disinfectant maintaining product contact time

• Approved disinfectant for COVID 19: quaternary ammonium compounds, sodium hypochlorite and 70% alcohol wipes

Patient Transport in the hospital

• Avoid the movement and transport of patients out of the isolation room or area unless medically necessary.

• The use of designated portable X-ray, ultrasound, echocardiogram and other important diagnostic machines is recommended when possible.

• If transport is unavoidable, the following should be observed:
  • Patients should wear a surgical mask during movement to contain secretions.
  • Use routes of transport that minimize exposures of staff, other patients, and visitors.
Notify the receiving area of the patient’s diagnosis and necessary precautions before the patient's arrival.

Ensure that healthcare workers (HCWs) who are transporting patients wear appropriate PPE if they will participate in direct patient care and perform hand hygiene afterward.

Area used by the patient/wheelchair to be cleaned appropriately after patient’s transfer.

**Patient Transport to another facility:**

- Inform the other facility about referring a suspected/confirmed case
- Call ambulance and inform about the case being suspected/confirmed COVID 19, which will be transferred in designated ambulance
- If hospital ambulance used ensure that ambulance will be cleaned and disinfected based on hospital guide
- If ambulance personnel will come in contact with the patient, they should wear appropriate PPE.

**Additional Measures**

- Dedicate HCWs and limit the number of persons present in the room to the absolute minimum required for the patient’s care and support
- Limit visitors entering the room to the minimum necessary.
- Keep log sheet of all persons coming in contact with the suspected/confirmed COVID 19 patients
- Exclude immunocompromised, pregnant, non-competent staff from the care of suspected/confirmed COVID 19 patients

**Aerosol- generating procedures**

Below are most common Aerosol- generating procedures:

- Cardiopulmonary resuscitation
- Intubation
- Extubation
- High flow nasal oxygen
- Non-Invasive ventilation: BiPAP/CPAP
- Open suction
- Ambu Bagging
- Bronchoscopy
- Tracheostomy
- Upper GI endoscopy
- Dental Procedures
- Nebulizer therapy
- Sputum induction
Environmental cleaning in isolation rooms/areas

- Ensure that environmental cleaning and disinfection procedures are followed consistently and correctly
- Increase frequency of cleaning by housekeeping in patient care areas especially high touch surfaces (door handle, call bell, patient side rails ...etc.)
- Isolation areas should have their own cleaning supplies that are separate from clean patient care areas and are kept in or near isolation area
- Responsible housekeeping staff should be trained and educated with regard to cleaning method and technique, donning and doffing of PPE, spill management, dealing with occupational exposure ...etc.)
- Cleaners/housekeeping should wear appropriate PPE when cleaning an isolation room or area
- All waste from the isolation area is considered contaminated and should be disposed of following your facilities methods for contaminated waste use Virkon or sodium hypochlorite for regular cleaning while patient is in the isolation room.
- After patient is discharged, use terminal cleaning with fumigation with accelerated hydrogen peroxide 6% or use UVC, time and cycles adjusted per room size and shape.

Linen and laundry management, food service utensils and waste management, related to COVID19 case

Refer to the facility guideline/ protocol for waste management, to be dealt with as infectious material

Managing Suspected /Confirmed case in Operation Theater

- Postpone elective operations immediately.
- Only emergency or medically necessary surgery should be performed
- Designate a specific operating theater for all COVID-19 cases. This room should be out of high-traffic areas and be completely emptied of all non-essential materials. When an anteroom is available, this should be used as an area for donning and doffing of personal protective equipment and exchange of equipment, medications and materials for the case.
- Use of personal protective equipment is recommended by the Centers for Disease Control for every operative procedure performed on a patient with confirmed COVID-19 infection or a patient where there is suspicion for infection.
- N95 respirators or respirators that offer a higher level of protection should be used when Performing, or present for, an aerosol-generating procedure (e.g. OR patient intubation) in COVID-19 or suspected infected patient.
- All traffic in and out of the operating theater should be minimized. A runner or support staff should be dedicated to the Operating Theater to provide all materials needed throughout the case with exchanges performed using a material exchange cart placed immediately outside of the room or in the anteroom.
- Procedures should be performed by senior and experienced staff to minimize procedure time.
Performing intubation and/or extubation in Operating Room (OR):

- Ideally intubate patients in an Airborne Infection Isolation Room (AII) room and then transfer them to the positive pressure OR (once intubated they are considered low risk because it is a closed system). Also consider transferring the patient to an AII room for extubation.
- If not possible, a portable high-efficiency particulate air (HEPA) filtration unit may be used by positioning the unit near the patient’s breathing zone.
- Switching the portable unit off during the surgical procedure.
- Only essential personnel wearing respiratory protection, such as an N95 respirator or PAPR, should be in the OR when intubation and extubation occur.
- A bacterial filter that filters particles 0.3 μm in size and has a filter efficiency of >95 percent should be placed on the patient’s anesthesia breathing circuit at the endotracheal tube or expiratory side of the circuit. The entire circuit should be changed after the surgery is completed.

After the procedure:

- The patient should be recovered in the operating theatre with dedicated staff until they can be transferred to an isolation room on the ward or in the intensive care unit.
- Adequate air exchanges should occur before environmental services enters the room for cleaning. With 15-20 air exchanges it will be around 30 minutes.

Managing bodies in the Mortuary

- Although no post-mortem transmission of COVID-19 has been documented, deceased bodies theoretically may pose a risk when handled by untrained personnel.

Preparing and packing the body for transfer from a patient room to mortuary

- The health worker attending to the dead body should follow standard precaution such as perform hand hygiene, ensure proper use of PPE (water resistant apron, goggles, N95 mask, gloves).
- All tubes, drains, and catheters on the dead body should be removed. Any puncture holes or wounds (resulting from removal of catheter, drains, tubes, or otherwise) should be contained with dressing.
- Keep both the movement and handling of the body to a minimum;
- There is no need to disinfect the body before transfer to the mortuary area;
- Place patient in leak-proof plastic body bag (Cadaver bags) and those handling the body at this point should use PPE (surgical mask, clean gloves, and isolation gown).
- If the family of the patient wishes to view the body at the time of removal from the isolation room or area, they may be allowed to do so with the application of **Standard Precautions** and should wash hands thoroughly with soap and water after the viewing.

- **Give the family clear instructions not to touch, kiss or hug the body, Adults >60 years and immunosuppressed persons should not directly interact with the body**

- Morgue’s staff should be informed about infectious status of the deceased, risk of infection and appropriate precautions required before transferring the patient to mortuary and should be well trained on standard precaution and infection control measure.

- Limit the number of Mortuary staff handling COVID dead body to limit the exposure

- No special transport equipment or vehicle is required. The trolley carrying the body must be disinfected after transmission with approved disinfectant (with 1% Hypochlorite solution, quarterly ammonium chloride ...etc)

- Dead bodies should be stored in cold chambers maintained at approximately 4°C

- The mortuary must be kept clean. Environmental surfaces, instruments and transport trolleys should be properly disinfected

**Preparing and transferring the body from mortuary to Graveyard**

- The body is prepared for burial in mortuary department of the healthcare facility as it is forbidden to transport it to the home and it is only allowed to move it to public washing places with trained and competent people with appropriate equipment to deal with the dead bodies of infectious diseases.

- Limit the number of people washing the body

- All personal performing the body wash should be competent and should wear appropriate PPE (gloves, mask, gown and face shield) and should thoroughly wash their hands with soap and water when finished

- Instruct the family to avoid large gathering at the burial ground it should limited to close family contacts

- The belongings of the deceased person do not need to be burned or otherwise disposed of. However, they should be handled with gloves and cleaned with a detergent followed by disinfection with a solution of at least 70% ethanol or 0.1% (1000 ppm) bleach, Clothing and other fabric belonging to the deceased should be machine washed with warm water at 60–90°C (140–194°F) and laundry detergent

- After removing the body, the mortuary fridge, door, handles and floor should be cleaned with approved disinfectant such as 1% Hypochlorite solution

- The vehicle, after the transfer of the body must be decontaminated
Surveillance

- Develop a database containing information for all suspected/confirmed case who were/are assessed at your facility.
- Develop a database containing information for all healthcare workers and visitors that were in contact /caring for the confirmed cases of COVID 19

Surge capacity

- Develop an emergency response plans to provide surge capacity, the plan should include human resources; staffed beds, ICU and non-ICU beds; critical equipment, supplies and other resources, including extra quantities of personal protective equipment, ventilators, ECMO machines, etc...

Guidance for Extended Use, Limited Reuse and decontamination of N95 Respirators during Pandemic

Disposable filtering facepiece respirators (FFRs) are not approved for routine decontamination and reuse as standard of care. However, FFR decontamination and reuse may need to be considered as a crisis capacity strategy to ensure continued availability.

As supplies of N95 respirators can become depleted during a pandemic or wide-spread outbreak of other infectious respiratory illnesses. Combination of approaches to conserve supplies are recommended, while safeguarding health care workers in such circumstances. These existing guidelines recommend that health care institutions:

- Prioritize the use of N95 respirators for **aerosol generating procedure only** and
- Minimize the number of individuals who need to use respiratory protection through the preferential use of engineering and administrative controls (**limit number of personal dealing with patient, cohorting the task of patient care Assigning designated teams of HCP...etc.**)
- Prioritize the use of N95 respirators for those personnel at the highest risk of contracting or experiencing complications of infection.
- Use alternatives to N95 respirators (e.g., other classes of filtering facepiece respirators, elastomeric half-mask and full facepiece air purifying respirators, powered air purifying respirators) where feasible;
- N95 respirators must only be used by a single wearer, prevent inadvertent sharing of respirators.
• All staff should be trained in proper technique of extended use of the mask such as (removing, storing and re-wearing it)

1. Definitions

1.1 Extended use: - refers to the practice of wearing the same N95 respirator for repeated close contact encounters with several patients, without removing the respirator between patient encounters. Extended use may be implemented when multiple patients are infected with the same respiratory pathogen and patients are placed together in dedicated waiting rooms or hospital wards.

1.2 Reuse: - refers to the practice of using the same N95 respirator for multiple encounters with patients but removing it (‘doffing’) after each encounter. The respirator is stored in between encounters to be put on again (‘donned’) prior to the next encounter with a patient.

2. Respirator Extended Use Recommendations

2.1 Discard N95 respirators

If contaminated with blood, respiratory or nasal secretions, or other bodily fluids from patients

➢ If used during aerosol generating procedures without face shield
➢ close contact with, or exit from, the care area of any patient co-infected with an infectious disease requiring contact precautions
➢ Obviously damaged or becomes hard to breathe through.

2.2 Consider use of a cleanable face shield (preferred) over an N95 respirator and/or other steps (e.g., masking patients, use of engineering controls), Or surgical mask if face shield is not available, when feasible, to reduce surface contamination of the respirator

2.3 Minimize unnecessary contact with the respirator surface, strict adherence to hand hygiene practices, and proper PPE donning and doffing technique, including physical inspection and performing a user seal check.

2.4 Mask can be re-use up to 5 times, no longer than 8 hours and decontaminated not more than manufactural recommendation and sterilization method

2.5 Ensure that the mask maintains its fitness after decontamination.

2.6 All supplies of N95 respirators should be stored in locked or secured, designated areas (ex. Unit Manager) and will be issued to staff with an appropriately handled paper bag or container that allows breathability.

2.7 N95 respirators must only be used by a single wearer, prevent inadvertent sharing of respirators.
3. **Instruction of reuse the N95 Mask**

3.1 Keep used respirators in a designated storage area or keep them in a clean, breathable container such as a paper bag between uses. To minimize potential cross-contamination, store respirators so that they do not touch each other and the person using the respirator is clearly identified. Storage containers should be disposed of or cleaned regularly.

3.2 Pack or store respirators between uses so that they do not become damaged or deformed.

3.3 Avoid touching the inside of the respirator. If inadvertent contact is made with the inside of the respirator, discard the respirator and perform hand hygiene.

3.4 Use a pair of clean (non-sterile) gloves when donning a used N95 respirator and performing a user seal check. Discard gloves after the N95 respirator is donned and any adjustments are made to ensure the respirator is sitting comfortably on your face with a good seal.

3.5 Strictly adhere to proper hand hygiene practices, and proper PPE donning and doffing technique.

4. **Decontamination of N95 mask**

4.1 **In Department Procedures**

4.1.1 Collect Plasma Sterilization pouch from CSSD.

4.1.2 Before use label the N95 respirator and paper storage bag with the user’s name, department, number of use and date to prevent reuse by another individual. Write name on mask where straps are attachment or on elastic straps of N95 mask and on plasma CSSD pouch.
4.1.3 **Do not** decontaminate mask more than 2 times with STERRAD sterilizer or 10 times with Steris sterilizer or more frequent based on manufacture recommendation.

4.1.4 You must wear full face shield over N95 mask to reduce risk of contamination especially if patient require Airborne and contact precaution such as COVID-19, varicella, etc.

4.1.5 Perform hand hygiene with soap and water or an alcohol-based hand sanitizer before and after touching or adjusting the respirator (if necessary, for comfort or to maintain fit).

4.1.6 Remove N95 mask carefully the front is potentially contaminated, so remove carefully by bending forward and using the elastic band.

4.1.7 After removing N-95, visually inspect for contamination, distortion in shape/form. If contaminated/wet, creased or bent, N95 should be discarded.

4.1.8 If the facemask is not visibly contaminated or distorted, carefully store in prepared CSSD pouch and seal with sterilization indicating tape to avoid destroying the shape of the mask place the pouch in designated CSSD container that with led cover in dirty utility room.

4.1.9 Send it to CSSD decontamination Room.

4.1.10 Clean and disinfect the storage box.

5. **In CSSD Department**
   5.1 Wear appropriate PPE (mask, gloves)
   5.2 Receive N95 Mask boxes by the CSSD staff and keep in dedicated trolley.
   5.3 Inspect receiving mask of visible damage and soil/contamination (e.g. blood, dried sputum, soil, bodily fluids).
   5.4 Any N95 respirator whose traceability was lost or number of decontamination cycles not able to be identified should be discarded.
   5.5 Decontaminated the mask based on manufactural recommendation of your N95 mask.
References:

6. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies: Jianjun Gao, Zhenxue Tian, Xu Yang
9. Lexi comp drug interaction index accessed 27th March 2020
10. Lexi comp drug information accessed 27th March 2020
12. Xueting Yao1 et al, In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Oxford University Press for the Infectious Diseases Society of America, 2020
16. PLOS Medicine | DOI: 10.1371/journal.pmed.1001967 March 1, 2016
19. King Faisal hospital protocol for COVID-19 Management
20. Effective Treatment of Severe COVID-19 Patients with Tocilizumab Xiaoling Xu1, #*, Mingfeng Yang
25. Pandemic Planning, Recommended Guidance for Extended Use and Limited Reuse of N95 filtering Face piece Respirators in Healthcare Settings, CDC, NIOSH Workplace Safety and Health Topics,
29. 3M Decontamination Methods for 3M N95 Respirators Technical Bulletin April, 2020 Revision 3
35. ICS Guidance for Prone Positioning of the Conscious COVID Patient 2020, Authors: Peter Bamford, Andrew Bentley, Jane Dean, David Whitmore and Noamaan Wilson-Baig
37. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia a,* a b c d Ruggero Capra, Nicola De Rossi, Flavia Mattioli, Giuseppe Romanelli, Cristina Scarpazza, Maria Pia Sormanie, Stefania Cossia elsweir https://doi.org/10.1016/j.ejim.2020.05.009
38. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 Raef Fadel, Austin Morrison, Amit Vahia, Zachary R Smith, Zohra Chaudhry, Pallavi Bhargava, Joseph Miller, Rachel Kenney, George Alangaden etal doi: https://doi.org/10.1101/2020.05.04.20074609
40. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial by Ivan Fan-Ngai Hung et al https://doi.org/10.1016/S0140-6736(20)31042-4
41. Lexicomp accessed 27th May 2020
42. Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture Aartjan J. W. te Velthuis1, Sjoerd H. E. van den Worm1, Amy C. Sims2, Ralph S. Baric2, Eric J. Snijder1*, Martijn J. van Hemert1*
Appendix I: Proper Use of PPE

COVID-19 Personal Protective Equipment (PPE) for Healthcare Personnel

- **Preferred PPE – Use**: N95 or Higher Respirator
  - Face shield or goggles
  - N95 or higher respirator
  - When respirators are not available, use the best available alternative, like a facemask.
  - One pair of clean, non-sterile gloves
  - Isolation gown

- **Acceptable Alternative PPE – Use**: Facemask
  - Face shield or goggles
  - Facemask
  - N95 or higher respirators are preferred, but facemasks are an acceptable alternative.
  - One pair of clean, non-sterile gloves
  - Isolation gown

See: [cdc.gov/COVID19](https://www.cdc.gov/COVID19)
Donning Personal Protective Equipment (PPE)

The following PPE sequence is specific to the situation requiring **Standard, Contact, and Airborne precautions**.

<table>
<thead>
<tr>
<th>Step</th>
<th>Coaching Sequence</th>
<th>Observed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Hand Hygiene</strong></td>
<td>1. Perform hand hygiene following WHO steps.</td>
<td>☐</td>
</tr>
<tr>
<td><strong>2. Gown</strong></td>
<td>1. Fully cover torso from neck to knees, arms to end of wrists, and wrap around the back. 2. Fasten gown by tying at the waist.</td>
<td>☐ ☐</td>
</tr>
<tr>
<td><strong>3. N95 Mask</strong></td>
<td>1. Cup the respirator in your hand with the nosepiece at fingertips, allowing the head straps to hang freely below hand. 2. Position the respirator under your chin with the nosepiece up while holding the respirator in place, pull the top strap over your head. 3. While continuing to hold the respirator firmly in place, pull the bottom strap over your head and position it below your ears. Untwist the straps. Position the respirator low on your nose. 4. Using both hands, mold the nosepiece to the shape of your nose by pushing inward while moving your fingertips down both sides of the nosepiece. 5. <strong>PERFORM A USER SEAL CHECK:</strong> Place both hands completely over the respirator, being careful not to disturb the position, and exhale sharply. If air leaks around your nose, adjust the nosepiece as described in step 5. If air leaks at respirator edges, adjust the straps back along the sides of your head.</td>
<td>☐ ☐ ☐ ☐ ☐</td>
</tr>
<tr>
<td><strong>4. Face Shield</strong></td>
<td>1. Place over face and eyes and adjust to fit.</td>
<td>☐</td>
</tr>
<tr>
<td>5. Put the Head Cover</td>
<td>1. Caps coverings must cover all hair, and jewelry must be removed or contained within the head.</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
Doffing Personal Protective Equipment (PPE)

**Standard, Contact, and Airborne precautions.** Always assume that the outside of your gloves, mask, and face shield and the front and sleeves of your gown are contaminated. Use particular caution when maneuvering near your face. Remove all your PPE inside the patient room except N95 mask, it will be removed outside.

<table>
<thead>
<tr>
<th>Step</th>
<th>Coaching Sequence</th>
<th>Observed</th>
</tr>
</thead>
</table>
| **1. Removing the Gloves** | 1. Inspect the gloves for any torn, tears or holes.  
2. Using a gloved hand, grasp the palm area of the other gloved hand and peel off first glove.  
3. Hold removed glove in gloved hand.  
4. Slide fingers of ungloved hand under remaining glove at wrist and peel off second glove over first glove.  
5. Discard gloves in a waste container. | ☐ ☐ ☐ ☐ ☐ |
| **2. Perform Hand Hygiene** | 1. Perform hand hygiene following WHO steps and adhere to proper timing *(count for 5 for each step)* | ☐ |
| **3. Remove the head cover** | 2. Remove the head cover from behind the head to front | ☐ |
| **4. Perform Hand Hygiene** | 1. Perform hand hygiene following WHO steps and adhere to proper timing *(count for 5 for each step)* | ☐ |
| **5. Removing the Face Shield/googles** | 1. Remove goggles or face shield from the back by lifting head band or ear pieces.  
2. Discard face shield in an infectious waste container.  
3. Decontaminate hands with alcohol-based hand sanitizer. | ☐ ☐ ☐ |
| **6. Perform Hand Hygiene** | 1. Perform hand hygiene following WHO steps and adhere to proper timing *(count for 5 for each step)* | ☐ |
7. Safely remove contaminated personal protective gowns

1. Unfasten ties
2. Pull away from neck and shoulders, touching inside of gown only
3. Turn gown inside out
4. Fold or roll into a bundle and discard

8. Perform Hand Hygiene

1. Perform hand hygiene following WHO steps and adhere to proper timing (count for 5 for each step)

9. Removing N95 Mask

1. If anti room is available remove your N95 mask in anteroom if not available then discard immediately outside patient room.
2. Without touching the respirator, slowly lift the bottom strap from around your neck up and over your head.
3. Lift off the top strap. Do not touch the respirator

10. Perform Hand Hygiene

1. Perform hand hygiene following WHO steps and adhere to proper timing (count for 5 for each step).
Appendix II: Flow diagram decision tool for conscious proning process

Figure 1 - Flow diagram decision tool for Conscious Proning process

FiO2 ≥ 28% or requiring basic respiratory support to achieve SaO2 92 – 96% (88-92% if risk of hypercapnic respiratory failure) AND suspected/confirmed COVID-19.

**Consider prone position if ability to:**
- Communicate and cooperate with procedure.
- Rotate to front and adjust position independently.
- No anticipated airway issues.

**Absolute contraindications:**
- Respiratory distress (RR ≥ 35, PaCO2 ≥ 6.5, accessory muscle use)
- Immediate need for intubation
- Haemodynamic instability (SBP < 90mmHg) or arrhythmia
- Agitation or altered mental status
- Unstable spine/thoracic injury/recent abdominal surgery

**Relative contraindications:**
- Facial injury
- Neurological issues (e.g. frequent seizures)
- Morbid obesity
- Pregnancy (2/3rd trimesters)
- Pressure sores / ulcers

YES

**Assist patient to prone position (See Table 1):**
- Explain procedure/benefit
- Ensure oxygen therapy and basic respiratory support secure with adequate length on the tubing
- Pillows may be required to support the chest
- Reverse Trendelenburg position may aid comfort
- Monitor oxygen saturations – If drop then ensure 02 connected and working
- Sedation must not be administered to facilitate proning

YES

**Monitor Oxygen Saturations for 15 minutes:**
SaO2 92-96% (88-92% if risk of hypercapnic respiratory failure) and nil obvious distress

YES

**Continue proning process (See Table 1):**
- Change position every 1-2 hrs aiming to achieve a prone time as long as possible
- When not prone aim to be sat at between 30-60 degrees upright
- Monitor oxygen saturations after every position change
- Titrated down oxygen requirements as able

YES

NO

**If deteriorating oxygen saturations:**
- Ensure oxygen is connected to patient
- Increase inspired oxygen
- Change patients position
- Consider return to supine position
- Escalate to critical care if appropriate

**Discontinue if:**
- No improvement with change of position
- Patient unable to tolerate position
- RR ≥ 35, looks tired, using accessory muscles

YES

NO

**Continue supine**
### Table: Timed position changes for patients undergoing conscious proning process

If patient fulfils criteria for proning ask the patient to switch positions as follows. Monitor oxygen saturations 15 minutes after each position change to ensure oxygen saturation has not decreased. Continue to monitor oxygen saturations as per the National Early Warning Score (NEWS)

- 30 minutes to 2 hours lying fully prone (bed flat)
- 30 minutes to 2 hours lying on right side (bed flat)
- 30 minutes to 2 hours sitting up (30-60 degrees) by adjusting head of the bed
- 30 minutes to 2 hours lying on left side (bed flat)
- 30 minutes to 2 hours lying prone again
- Continue to repeat the cycle

---

**COVID Awake Repositioning/ Proning Protocol (CARP)**

1. 30 minutes – 2 hours ➔ lying on your belly
2. 30 minutes – 2 hours ➔ laying on your right side
3. 30 minutes – 2 hours ➔ sitting up – 60 - 90 degrees
4. 30 minutes – 2 hours ➔ lying on your left side
Appendix III:

Informed consent to treatment with INVESTIGATIONAL medication

This is a consent form. Its purpose is to inform you about risks and benefits when using a new INVESTIGATIONAL drug in the management of your condition (COVID-19).

Treatment regimen could include one or more of the following drugs:

- 
- 
- 

Treatment duration:

I, __________________________, understand that there is no approved FDA treatment yet for the treatment of my current Infectious Illness (COVID19 infection).

In view of the current lack of other safe and effective alternatives, I give my consent for being treated with above mentioned investigational drug/drugs by my managing team.

I acknowledge that possible common drug-related side effects have been explained to me.

Hospital name: 

Physician name: _______ staff number: _______ signature: _______

Witness name: _______ staff number: _______ signature: _______

Patient’s name (next of kin) name and signature: ____________

Date/time: ________________________________
موافقة المسبقة على العلاج بالأدوية التجريبية

هذا نموذج موافقة. الغرض منه هو إبلاغك بالمخاطر والفوائد عند استخدام دواء تجريبي جديد في إدارة حالتك (كوفيد-19).

يمكن أن يشمل نظام العلاج واحدًا أو أكثر من الأدوية التالية:

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

مدة العلاج:

أنا، ____________________________ أفهم أنني لا يوجد علاج معتمد من إدارة الغذاء والدواء حتى الآن لعلاج مرضي المعدني الحالي (كوفيد-19).

في ضوء النقص الحالي في البديل الأخرى الآمنة والفعالة، أمنح موافقتى على العلاج بالعقار/العقاقير التجريبية المذكورة أعلاه من قبل الفريق الطبي.

أقر بأن الأعراض الجانبية الشائعة المتعلقة بالعقار قد تم شرحها لي.

اسم المستشفى: ____________________________

اسم الطبيب: ____________________________ رقم الموظف: ____________________________ التوقيع: ____________________________

اسم الشاهد: ____________________________ رقم الموظف: ____________________________ التوقيع: ____________________________

اسم المريض (أقرب الأقرباء) وتوقيعه: ____________________________
التاريخ / الوقت: ____________________________

Name of the Hospital: ____________________________

Name of the Doctor: ____________________________ Employee ID: ____________________________ Signature: ____________________________

Name of the Witness: ____________________________ Employee ID: ____________________________ Signature: ____________________________

Name of the Patient (Closest Relative): ____________________________
Signature: ____________________________
Date / Time: ____________________________
Appendix: IV

Informed consent to treatment with OFF-LABEL medications

This is a consent form. Its purpose is to inform you about risks and benefits when using an OFF-LABEL drug in the management plan of your condition, covid-19 (SARS coV2 Infection)

Any of the following treatment regimen:

Lopinavir-Ritonavir 2 tablets per oral daily every 12 hours
Interferon 1-B 180 microgram Subcutaneous once per week
Favipiravir 1600 mg twice a day for 1 day then 600 mg twice a day

Other treatment as indicated

Treatment duration:

5-10 days

I _______________________, understand that medication listed above are all FDA approved for other medical indications with proven safety and efficacy, and they are not approved yet for the treatment of my acute infectious illness (2019 Novel Corona Virus Infection).

In view of the current lack of other safe and effective alternatives, I give my consent for being treated with one or a combination of above drugs by my managing team.

I acknowledge that possible drug-related side effects have been explained to me (drug allergy, skin rash, mild anaemia, loose motions)

Hospital name:

Physician name: staff number signature:

Witness name: staff number: signature:

Patient’s name (next of kin): signature:

Date: Time:
الموافقة المسبقة على العلاج بالأدوية لغير استخدامها المعتمد

هذا نموذج موافقة. الغرض منه هو إبلاغك بالمخاطر والفوائد عند استخدام دواء لغير استخدامها المعتمد في خطة إدارة حالتك (كوفيد – 19).

نظام العلاج:

حبة يومياً عن طريق الفم كل 12 ساعة Lopinavir-Ritonavir
180 ميكروغرام تحت الجلد مرة واحدة في الأسبوع Interferon 1-B
1600 ملغ في اليوم الأول ثم 600 ملغ يوميا Favipiravir
أي علاج آخر تستدعه حالتي

مدة العلاج:

5-10 يوم

أنا __________________________ أثناء قراءة هذا النموذج، فهمت أن الأدوية المذكورة أعلاه معتمدة من قبل هيئة الغذاء والدواء لاستخدامها في مكافحة كوفيد-19.

في ضوء النقص الحالي في البدائل الأخرى الأمنة والفعالة، فأنا أعطي موافقة على العلاج بالدواء المذكور دون تأجيل مدة النجاعة أو استبداله بدواء آخر.

أقر بأن الأعراض الجانبية المحتملة المتعلقة بالأدوية قد تم شرحها لي (حساسية، طفح جلدي، فقر دم، اسهال).

اسم المستشفى: _______________________________

اسم الطبيب: ___________________ رقم الموظف: ___________________ التوقيع: _______________________

اسم الشاهد: ___________________ رقم الموظف: ___________________ التوقيع: _______________________

اسم المريض (أقرب الأقرباء): ___________________ التوقيع: _______________________

التاريخ: ___________________ الوقت: ___________________
Appendix: V- Home Quarantine Consent

Undertaken to implement the home quarantine procedure

I the under-designed, declare that I was notified about the health procedures and the medical advices that I should follow, and that I am aware of the risks that could happen to the society in case I am not committed to them, so for the sake of the public health and to avoid the legal accountability I hereby declare that I will not leave the house and I will consider not to get in contact with others as much as I can until the required health measures end, and the duration of the quarantine is 7 days starting from ________________ (decided by health authority)

This is my acknowledgment that I have been notified of the above mentioned.

Name: ______________________________

Passport / ID No.: ______________________

Mobile number: ____________________________

Home address: ____________________________

Number of friend/sponsor/next of kin:

Email address: ____________________________

Signature: _______________________________

Date: _____/_______/_______

اقرار وتعهد بتنفيذ اجراءات الحجر الصحي
انا الموقع ادناه اتعهد بأنه تم إبلاغي بالإجراءات الصحية والنصائح الطبية الواجب اتباعها، وإنني أدرك المخاطر التي من الممكن أن تلحق بالمجتمع في حال عدم التزامي، لذا حرصا على الصحة العامة وتجنب المساكل القانونية اتعهد بعدم مغادرة المنزل مع مراعاة تجنب مخالطة الاخرين قبل الامكان حتى نهاية الاجراءات الصحية المطلوبة وفترة الحجر الصحي لمدة 7 يوما اعتبارا من تاريخ ________________ (تحدد الجهة الصحية)

والذلك اقرارا مني بأنه تم إخطارني بما ذكر أعلاه

الاسم: ..............................................................

رقم الجواز/ الهوية الوطنية: ..............................................................

رقم الهاتف المتحرك: ..............................................................

عنوان المنزل: ..............................................................

البريد الإلكتروني: ..............................................................

رقم أحد الأقارب أو الكفل: ..............................................................

التوقيع: _______________________________

التاريخ: ........../........../..........
### Instructions for HOME Quarantine for (COVID-19)

<table>
<thead>
<tr>
<th>Step</th>
<th>Instruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Stay at home in a single room with separate washroom and separate yourself from other people in your home.</td>
</tr>
<tr>
<td>2.</td>
<td>If you share any facility at home, please make sure you disinfect it thoroughly after every use with warm water and detergent then dry your items with a separate towel that only you would use.</td>
</tr>
<tr>
<td>3.</td>
<td>Don’t go outside your room, unless it’s unavoidable and then wear a facemask.</td>
</tr>
<tr>
<td>4.</td>
<td>Cover your mouth and nose when you cough or sneeze with tissue then dispose of it immediately in a sealed plastic bag.</td>
</tr>
<tr>
<td>5.</td>
<td>Wash your hands frequently with soap and water for 20 seconds at least then dry them well and avoid touching your eyes, nose and mouth if you haven’t washed your hands.</td>
</tr>
<tr>
<td>6.</td>
<td>Avoid sharing household items.</td>
</tr>
<tr>
<td>7.</td>
<td>Monitor your symptoms (Breathing difficulty, Fever, Sore throat, Cough, Runny nose, Headache) and check your temperature daily. (or the person you are caring for, as appropriate).</td>
</tr>
<tr>
<td>8.</td>
<td>Do not have visitors in your home.</td>
</tr>
<tr>
<td>9.</td>
<td>If you have pets in the household, try to keep away from your pets. If this is unavoidable, wash your hands before and after contact.</td>
</tr>
<tr>
<td>10.</td>
<td>Waste management: All waste that has been in contact with the individual, including used tissues, and masks if used, should be put in a plastic rubbish bag and tied when full. The plastic bag should then be placed in a second bin bag and tied.</td>
</tr>
<tr>
<td>11.</td>
<td>If you need to visit your doctor, call ahead before visiting.</td>
</tr>
</tbody>
</table>

---

If you develop any active complaints (fever, body aches, headache, cough, throat pain or shortness of breath) during home quarantine period, please contact one of the following numbers for advice:

- **8001717**: The Operation Center, Department Of Health
- **80011111**: Ministry Of Health And Prevention
- **800342**: Dubai Health Authority
Appendix VI: COVID-19 Treatment Options Index

Dosing & frequency mentioned is for normal renal & hepatic functions

For moderate to severe hepatic or renal impairment dosing, other drug interactions etc.

(Please consult the on-call pharmacist)

For further information on these medications please refer to the clinical pharmacist/pharmacist at your facility

Lopinavir/Ritonavir:

Lopinavir was shown to have in vitro activity against both SARS-CoV-1 and MERS-CoV in some studies.

A recent randomized, controlled, open-label trial assessed lopinavir-ritonavir (n=99) vs. standard of care (n=100) in SARS-CoV-2 patients showed that:

- Treatment with LPV/r was not associated with a difference in time to clinical improvement or mortality
- Randomization didn’t occur until a median of 13 days after symptom onset however, so the window for benefit may have already closed.

Therefore, Lopinavir/Ritonavir should not be used as a monotherapy and to be used in mild to moderate confirmed cases not in severe cases.

Although all the protease inhibitors have precautions about worsening or causing liver toxicity, Tipranavir is the only protease inhibitor that carry a black box warning for potentially fatal hepatotoxicity and fatal and nonfatal intracranial hemorrhage.

Abnormal fat redistribution syndrome is a big concern, it consists of two distinct syndromes:

1. Lipohypertrophy, or central body fat accumulation characterized by a "dorsal fat pad," increased abdominal girth, and increased breast size in women, and
2. Lipoatrophy, or peripheral wasting of face, buttocks, and extremities.

Dosage Recommendations:

Adult: 800 mg lopinavir /200 mg ritonavir once daily.

Pediatric:

Weight: 15 to 20 kg 200 mg /50 mg bid

>20 to 30 kg 300 mg / 75 mg bid

>30 kg 400 mg / 100 mg bid
Dose adjustment:

Once daily is not recommended for pregnant women, children below 18 years of age, hemodialysis or patient taking enzyme inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine). (Dividing the dose every 12 hours is preferred).

No dose adjustment requires for renal or hepatic impairment (Some degree of serum aminotransferase elevations may occur, could reach >5 times the upper limit of normal), however, it is a transient elevation, discontinuation of therapy is not required, as most patients recover spontaneously with continued treatment.

Administration:

Take the tablet with food swallow whole without crushing chewing or break. (Food can decrease GI side effects and increase Tolerability).

Monitoring:

- A baseline of:
  1. Hepatitis B screening (surface antigen or antibody) and hepatitis C antibody.
  2. Fasting blood glucose or HbA1c. (Patients with a family history of diabetes mellitus may be at a greater risk, and demand a close monitoring).
  3. Fasting lipid profile. (For patient with cardiovascular risk or on estrogens or atypical antiphsycotics or interferon alpha).
  4. ALT, AST, and total bilirubin. (Repeat after 2 weeks).

- Pregnancy test.

Common Side effects:

- Dyslipidemias and Lipodystrophy.
- Elevated liver enzymes. (Found in 3% to 10% of patients, although rates may be higher in patients with HIVor HCV coinfections).
- Increase blood glucose level.
- Gastrointestinal disturbances including: diarrhea, nausea and vomiting. (Before starting prescriber should take into his consideration manifestation of the disease (accompanied digestive symptoms) and rule out liver insufficiency).
- Headache
- QT prolongation ≤ 2% of patients. (QT interval should be observed when is taken with other drugs that might induce QT prolongation).
Drug-Drug Interactions with other anti-covid-19:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloroquine</td>
<td>Co-administration has not been studied.</td>
<td>No dosage adjustment is recommended for Chloroquine but monitor toxicity.</td>
</tr>
<tr>
<td></td>
<td>Lopinavir/ritonavir could potentially increase chloroquine exposure to a moderate extent due to the multiple elimination pathways.</td>
<td>Caution is advised when prescribing Lopinavir/ritonavir and medicinal products known to induce QT interval prolongation such as Chloroquine.</td>
</tr>
</tbody>
</table>

Chloroquine OR Hydroxychloroquine:

Chloroquine has a modest effect by itself but has synergistic effect when combined with selected antiretrovirals (such as: zidovudine and didanosine). These in-vitro results warrant in-vivo confirmation.

An expert consensus group out of China suggests that chloroquine improved lung imaging and shortened disease course.

Hydroxychloroquine was found to be more potent than chloroquine in inhibiting SARS-CoV-2 in vitro.

Dosage Recommendations:

The concentration of chloroquine in the plasma reached 10 μM when a daily intake of 500 mg was prescribed. Researchers found that to inhibit SARS-CoV replication by 99% three days postinfection, 16 μM chloroquine was needed, therefore the required daily dose is **500 mg bid chloroquine phosphate**.

Hydroxychloroquine sulfate a loading dose of 400 mg twice daily day 1, followed by a maintenance dose of 200 mg twice daily for 5-7 days.

Administration:

Administer with meals to decrease GI upset.

Monitoring:

- **A baseline of:**
  1. Discontinue and avoid all other non-critical QT prolonging agents.
  2. Assess a baseline ECG, renal function, hepatic function, serum potassium and serum magnesium.
  3. When possible, have an experienced cardiologist/electrophysiologist measure QTc, and seek pharmacist input in the setting of acute renal or hepatic failure.
  4. CBC
  5. G6PD level

- **Ongoing:**
  1. Place on telemetry prior to start of therapy
3. Acquire an ECG 2-3 hours after the second dose of hydroxychloroquine, and daily thereafter.
4. If QTc increases by >60 msec or absolute QTc >500msec (or >530-550 msec if QRS >120 msec), discontinue azithromycin (if used) and/or reduce dose of hydroxychloroquine and repeat ECG daily.
5. If QTc remains increased >60 msec and/or absolute QTc >500 msec (or >530-550 msec if QRS >120 msec), reevaluate the risk/benefit of ongoing therapy, consider consultation with an electrophysiologist, and consider discontinuation of hydroxychloroquine.

**Common Side effects:**

Cardiovascular: Atrioventricular block, bundle branch block, cardiac arrhythmia, cardiomyopathy (mostly with prolonged use), ECG changes (including prolonged QRS and QTc intervals) if administered in combination with other QTc-prolonging agents such as azithromycin, metoclopramide, ondansetron, haloperidol, quetiapine ...etc)

Endocrine metabolic: Hypoglycemia

Gastrointestinal: Abdominal cramps, anorexia, diarrhea, nausea, vomiting.

Central nervous system: Agitation, anxiety, confusion, decreased deep tendon reflex, delirium, depression, extrapyramidal reaction.

Ophthalmic: Disorder of macula of retina, Retinal disorder.

**Drug-Drug Interactions with other anti-covid-19:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lopinavir/Ritonavir</td>
<td>Co-administration has not been studied.</td>
<td>No dosage adjustment is recommended for Chloroquine but monitor toxicity.</td>
</tr>
<tr>
<td></td>
<td>Lopinavir/ritonavir could potentially increase chloroquine exposure to a moderate extent due to the multiple elimination pathways.</td>
<td>Caution is advised when prescribing Lopinavir/ritonavir and medicinal products known to induce QT interval prolongation such as Chloroquine.</td>
</tr>
</tbody>
</table>
**Remdesivir:**

It is an experimental broad-spectrum antiviral agent, which was synthesized and developed in 2017 as a treatment for Ebola virus infection.

In-vitro studies showed that remdesivir can inhibit coronaviruses such as SARS-CoV and MERS-CoV replication, and against SARS-CoV-2.

Preclinical randomized, controlled, double blind trials are conducted to evaluate the efficacy and safety of remdesivir in patients with moderate and severe COVID-19 respiratory disease.

**Dosage Recommendations:**

The dose which is used in these trials is 200 mg loading dose on day 1 followed by 100 mg once-daily for 9 days. Which is the same dose which was used before in Ebola Virus 2019 trial.

**Administration:**

IV infusion.

**Monitoring:**

- A baseline of:
  1. CBC
  2. Renal and liver functions

**Common Side effects:**

- Hypotension, anaphylactic shock, diarrhea, constipation, nausea and vomiting.
- Elevated liver function tests (AST, ALT), phlebitis and headache.
- Remdesivir is co-formulated with sulfobutyl ether β-cyclodextrin (SBEC), so there is a theoretical risk of accumulation in renal failure promoting further renal injury, similar to intravenous voriconazole. Especially if creatinine clearance is < 50 ml/minute

**Drug-Drug Interactions with other anti-covid-19:**

No interaction documented so far.

**Favipiravir**

A novel pyrazine derivative, an inhibitor of influenza RNA dependent RNA polymerase that is active against influenza A, B, and C viruses, including oseltamivir-resistant variants.

A prospective study was conducted in 2019 to compare the clinical effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection.

In this small study the results showed that the combination therapy can accelerate the recovery compared to oseltamivir alone.
In Vitro Favipiravir showed significant activity against a huge range of RNA viruses including rabies and influenza viruses.

A study of Ebolavirus-infected mice showed that favipiravir treatment reduced viral loads and improved survival. A clinical trial in which all patients with Ebolavirus infection were given favipiravir (6 g initially; then 2.4 g daily) showed a decrease in Ebolavirus RNA by 0.3 log10/day. (QT interval prolongation is a concern with this high dose), furthermore, the dose of 6 g loading requires 30 tablets which deems difficult to swallow.

**Dosage Recommendations:**

The dose regimens assessed in the combination trial were based on the approved favipiravir regimen in Japan (two 1600 mg oral loading doses on day 1, followed by 600 mg twice daily (BID) on days 2–5) and on the higher one (1800 mg BID on day 1 followed by 800 mg BID thereafter) tested in randomized, placebo-controlled phase 3 treatment trials outside of Japan.

Clinical use of up to 3.6g on first day followed by 800mg twice daily can be considered safe according to the WHO guidelines for ebola treatment.

The recommended dose by WHO for covid-19 is 1600 mg BID loading then 600 mg TID for 5-7 days.

**Administration:**

Orally.

**Monitoring:**

- A baseline of:
  
  Liver functions. (Repeat after 1 week).

**Common Side effects:**

Transient elevation in serum alanine aminotransferase.

QT prolongation with high doses or if administered in combination with other QTc-prolonging agents such as chloroquine, hydroxychloroquine, azithromycin, metoclopramide, ondansetron, haloperidol, quetiapine ...etc)

**Drug-Drug Interactions with other anti-covid-19:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol</td>
<td>Potential increase of paracetamol level by 14-16%</td>
<td>Observe liver function closely, if elevated reduce paracetamol dose.</td>
</tr>
</tbody>
</table>
**Interferon alpha**

In a 2013 systematic review there was only one randomized controlled trial compared ribavirin with interferon-1a which showed no advantage of ribavirin over interferon in patients with SARS. In addition, there were observational studies comparing Interferon-1a with untreated controls. Interferon led to improvements in clinical and laboratory parameters compared with control patients. However, there was no standard regime used and adverse events were not well documented.

**Dosage Recommendations:**

**Adults:** Starting with 9mcg/daily for at least 2 days, then 15 mcg/daily if no response for 8-13 days. (subcutaneously).

**Pediatric:** 2–4 mcg/kg in 2 mL sterile water, twice daily for 5–7 days (Nebulization).

**Administration:**

Subcutaneous injection

Nebulization

**Monitoring:**

- A baseline of:
  
  (Repeat during therapy if clinically indicated): Chest x-ray, serum creatinine, albumin, prothrombin time, triglycerides.

  CBC, liver function, renal function, electrolytes and TSH, ophthalmic exam, ECG (in patients with pre-existing cardiac abnormalities or in advanced stages of cancer). (repeat liver function after 2 weeks).

**Common Side effects:**

- Central nervous system: Fatigue, headache, chills, rigors, depression, drowsiness, dizziness, vertigo, irritability.

- Gastrointestinal disturbances including: diarrhea, nausea and vomiting.

- Hematology: Neutropenia, granulocytopenia, leukopenia, anemia, thrombocytopenia.

- Elevated liver enzymes

- Neuromuscular & skeletal: Myalgia

- Flu-like symptoms

**Drug-Drug Interactions with other anti-covid-19:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Interaction</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tocilizumab and Sarilumab</td>
<td>Bone marrow suppression</td>
<td>Avoid these drugs for at least 3 day after INF administration</td>
</tr>
</tbody>
</table>
**Tocilizumab and Sarilumab**

IL-6 inhibitors are FDA approved for cytokine release syndrome complications related.

IL-6 and ferritin levels elevation is reported to correlate with severe COVID-19 cases.

Retrospective reviews in patients with rheumatological disease suggest a possible increase in serious bacterial infection, so use caution if secondary infection is clinically suspected.

**Dosage Recommendations:**

**Tocilizumab**: 4-8mg/kg (suggested dose 400 mg) IV x1. Dose may be repeated 12 hours later if inadequate response to the first dose. The total dose should be no more than 800 mg per dose. Tocilizumab should not be administered more than twice.

**Sarilumab**: 200 – 400 mg single dose.

**Administration:**

Intravenous infusion. (To be infused over 60 minutes). (For further details about IV preparation please call the pharmacist).

**Monitoring:**

- A baseline of:
  1. Latent TB
  2. CBC
  3. Liver enzymes.
  4. Lipid profile.
  5. Ferritin, IL-6 & CRP

**Common Side effects:**

- Elevated liver enzymes.
- Infusion reaction.
- Hypercholesterolemia.
- Neutropenia.

**Drug-Drug Interactions with other anti-covid-19:**

No interaction documented so far.

**Camostat**

A serine protease inhibitor which was displayed antiviral activity in a pathogenic animal model for SARS-CoV1 infection.

It inhibits the enzymatic activity of cell-surface proteases involved in coronavirus activation. and the resultant production of inflammatory cytokines possibly through inhibition of transmembrane proteases activities.

**Dosage Recommendations:**
200 mg TID and adjust upon response

**Administration:**
Oral with meal.

**Monitoring:**
- A baseline of:
  1. CBC
  2. Liver enzymes.
  3. Electrolytes.
  4. Ferritin & CRP

**Side effects:**
- Rarely GI disturbances & elevated liver enzymes

**Drug-Drug Interactions with other anti-covid-19:**
No interaction documented so far.

---

**Zinc**

Multiple meta-analyses and pooled analyses of randomized controlled trials (RCTs) have shown that oral zinc supplementation reduces the incidence rate of acute respiratory infections by 35%, shortens the duration of flu-like symptoms by approximately 2 days, and improves the rate of recovery.

The mechanisms by which zinc alters human susceptibility to acute lower respiratory infection likely include the regulation of pro-inflammatory cytokine secretion, lymphocyte proliferation, T lymphocyte function and protection of the integrity of respiratory epithelial cells in the setting of acute inflammatory lung injury.

**Dosage Recommendations:**
100 mg elemental zinc daily.

**Administration:**
Administer 1 hour after meal.

**Side effects:**
- Rarely GI disturbances & elevated liver enzymes

**Drug-Drug Interactions with other anti-covid-19:**
No interaction documented so far.

---

**Vitamin C (Ascorbic acid)**
It acts as an antioxidant, limiting inflammation and tissue damage associated with immune response.

In six trials, orally administered vitamin C in doses of 1–3 g/day reduced the length of ICU stay by 8.6% and in three trials shortened the duration of mechanical ventilation by 18.2%.

Currently a trial using for high-dose IV vitamin C in COVID-19 patients in China is conducted and slated to be complete in the fall of 2020.

**Dosage Recommendations:**

Oral or IV 1-3 g daily. (For more details about IV preparation please call the pharmacist).

**Administration:**

Administer orally with food.

**Common Side effects:**

Hyperoxaluria (with high dose)

**Drug-Drug Interactions with other anti-covid-19:**

No interaction documented so far.